

## VERIFICATION OF TRANSLATION

I, Mikiko Oyanagi

of 6th Fl., Kantetsu Tsukuba-Science-City Bldg. 1-1-1, Oroshi-machi, Tsuchiura, Ibaraki,  
JAPAN

declare as follows:

1. That I am well acquainted with both the English and Japanese languages, and
2. That the attached document is a true and correct translation of a certified copy of the following application, which was made by me to the best of my knowledge and belief.

(a) Japanese Patent Application No. 2002-255442

Entitled: "NOVEL ACTIN-RELATED CYTOSKELETAL PROTEIN "LACS""

Filed on August 30, 2002

June 22, 2007  
(Date)

Mikiko Oyanagi  
(Signature of Translator)

Mikiko Oyanagi

**【Name of Document】** APPLICATION FOR PATENT

**【Identification Number】** MED-A0206

**【Special Mention】** Patent Application under the provision of Article 30, paragraph 1 of Patent Law

**【Filing Date】** August 30, 2002

**【Addressee】** Esq. Commissioner of the Patent Office

**【Inventor】**

**【Address】** 101, Aquacourt 2bankan,  
3-5-2, Momochihama, Sawara-ku, Fukuoka-shi, FUKUOKA

**【Name】** EGASHIRA, Kensuke

**【Inventor】**

**【Address】** 503, Yuhaimu Akasaka Minami,  
2-2-4, Kego, Chuo-ku, Fukuoka-shi, FUKUOKA

**【Name】** INOUE, Shujiro

**【Applicant】**

**【Identification Number】** 500409323

**【Name or Appellation】** AnGes MG, Inc.

**【Attorney】**

**【Identification Number】** 100102978

**【Patent Attorney】**

**【Name or Appellation】** Hatsushi Shimizu

**【Nominated Attorney】**

**【Identification Number】** 100108774

**【Patent Attorney】**

**【Name or Appellation】** Kazunori Hashimoto

**【Payment】**

**【Registration Number】** 041092

**【Amount】** 21000

**【List of Attached Documents】**

【Name of Document】	Description	1
【Name of Document】	Abstract	1
【Proof】	Necessary	

[Document Name] Specification

[Title of the Invention] NOVEL ACTIN-RELATED CYTOSKELETAL PROTEIN "LACS"

[Claims]

[Claim1] A protein selected from (a) to (d):

- 5 (a) a protein comprising the amino acid sequence of SEQ ID NO: 1;  
(b) a protein comprising the amino acid sequence of SEQ ID NO: 1, wherein one or more amino acids have been modified by deletion, substitution, addition, and/or insertion;  
(c) a protein comprising a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID NO:  
10 2; and  
(d) a protein comprising an amino acid sequence having 60% homology to the amino acid sequence of SEQ ID NO: 1.

[Claim2] A polynucleotide encoding the protein of claim 1 or a portion thereof.

15 [Claim3] The polynucleotide of claim 2, which comprises the nucleotide sequence of SEQ ID NO: 2.

[Claim4] A pharmaceutical comprising the protein of claim 1.

[Claim5] The pharmaceutical of claim 4, which is used to prevent, improve, or treat cardiac failure, cardiomegaly, myocarditis, or cardiomyopathy.

[Claim6] A pharmaceutical comprising the polynucleotide of claim 2.

20 [Claim7] The pharmaceutical of claim 6, which is used to prevent, improve, or treat cardiac failure, cardiomegaly, myocarditis, or cardiomyopathy.

[Detailed Description of the Invention]

[0001]

[Technical Field of Industrial Application]

25 The present invention relates to novel actin-related cytoskeletal proteins, and genes encoding the proteins. Furthermore, the present invention relates to inventions utilizing the proteins and genes of this invention, such as pharmaceuticals comprising the proteins or genes as active ingredients.

[0002]

30 [Prior Art]

Nitric oxide (NO) (Moncada and Higgs, Eur. J. Clin. Invest. 21 (4): 361-74 (1991)) is a messenger molecule that takes on various physiological roles in the cardiovascular, nervous, and immune systems (Griffith *et al.*, J. Am. Coll. Cardiol 12: 797-806 (1998)). NO is produced together with L-citrulline from vascular endothelial cells, using arginine as a  
35 substrate and two types of nitric oxide synthases (NOSs; cNOS (constitutive) and iNOS (inductive); Bredt and Snyder, Proc. Natl. Acad. Sci. USA 87: 682-5 (1990); Janssens *et al.*, J.

Biol. Chem. 267: 22964 (1992); Lyons *et al.*, J. Biol. Chem. 267: 6370-4 (1992)). Reports show that NO is involved in: (1) vasodilation mediated by vascular endothelial cells (Tanner *et al.*, Circulation 83: 2012-20 (1991)); (2) inhibition of vascular intimal thickening (Garg and Hassid, J. Clin. Invest. 83: 1774-7 (1989)); (3) mediation of vasodilation in nonadrenergic noncholinergic nerves; (4) nerve cell death; (5) action as a neurotransmitter; (6) long-term potentiation and long-term depression of memory; (7) bactericidal effect of macrophages and neutrophils; (8) release of insulin from pancreatic  $\beta$ -cells (Life Science 49: L213-7 (1991)); (9) carcinogenesis (Gastrolenterology 103: 1260-6 (1992)); (10) antiplatelet effect (Radomski *et al.*, Proc. Natl. Acad. Sci. USA 87: 5193-7 (1990)); and such. NO also has various antiarteriosclerotic and cardioprotective functions in the cardiovascular system. Thus, administration of NO synthase inhibitors causes cardiovascular remodeling such as inflammatory and proliferative changes in the cardiovascular tissues, thickening of the tunica media, perivascular fibrosis, and cardiomegaly.

[0003]

L-NAME ( $N^G$ -Nitro-L-arginine methyl ester, hydrochloride) is a widely used NO synthase inhibitor that inhibits cNOS and iNOS. Continuous administration of L-NAME to rats can produce rats with inhibited NO production. In such model rats, increase of blood pressure as well as cardiovascular inflammatory and proliferative changes (infiltration of monocytes/macrophages, increase of MCP-1, elevation of NF- $\kappa$ B activity, etc.) occur within one week of L-NAME administration, and cardiovascular remodeling is observed from the fourth week onwards. Eventually, the rats die due to cardiac failure, renal failure, cerebral infarction, or such. Inflammatory and proliferative changes and arteriosclerotic lesions in rats with inhibited NO production are known to disappear when the effects of angiotensin II (AngII) or MCP-1 are suppressed.

[0004]

Rho is a low-molecular-weight G protein that regulates the adhesion of cells to the extracellular matrix and vascular endothelium, and is involved in various processes including cell-substrate adhesion, cell migration, neurite retraction, cytokinesis, and cell cycle progression from  $G_1$  to S phase. Many of these effects are due to the rearrangement of the actin cytoskeleton. The actin cytoskeleton is modulated by using Rho-regulated adhesion as a supporting point, and it enables the migration of cells into tissues and passing of cells through intercellular space. Rho is inactive in the GDP-bound form, and becomes active upon GTP binding. The activated GTP-bound Rho acts on effector molecules that are further downstream in the pathway. Rho-associated kinase (Rho-associated coiled-coil-forming protein kinase; ROCK) is a protein kinase and one of the Rho downstream effectors. Rho induction of the actin cytoskeleton occurs at different locations in the cell cycle to produce

different skeletons of specific forms.

[0005]

ROCK is a serine/threonine kinase having a molecular weight of 160 kDa. It has a kinase domain at the N terminus, a coiled-coil-forming region in the middle, and a membrane-bound domain at the C terminus. Previous analyses have shown that ROCK regulates the actin skeleton through a number of pathways (M. Maekawa *et al.*, Science 285: 895-8 (1999)). In one of the pathways, myosin phosphatase is inactivated, and myosin is activated by directly phosphorylating the myosin light chain to induce actomyosin contraction. Another pathway involves the activation of LIM kinase. Activated LIM kinase becomes inactive upon phosphorylation of the actin-binding protein cofilin. As a result, the actin depolymerization activity of cofilin is suppressed, increasing filamentous actin. Yet another pathway involves phosphoactivation of Na<sup>+</sup>/H<sup>+</sup> exchanger isoform-1. Upon activation, the exchanger promotes binding of the ERM (Ezrin/Radixin/Moesin) protein, and induces the binding of actin to cell membrane. ROCK is considered to contribute to the formation of cell membrane-bound actomyosin bundles through such pathways.

[0006]

[Problems to be Solved by the Invention]

The present inventors have reported that NO-mediated changes in cardiovascular remodeling can occur due to a local increase of angiotensin convertase (ACE) activity in cardiac tissues, and can be suppressed almost completely by ACE inhibitors and angiotensin II receptor (AT1R) antagonists. However, many facts still remain unclear such as the mechanism of local activation of the renin-angiotensin system (RAS), the mechanism involved in the changes of cardiovascular architecture following signaling, etc. Thus, identification of genes that play important roles in the development of cardiovascular lesions is desired. Such genes and proteins encoded by these genes are also considered to be important in terms of the prevention and treatment of cardiac diseases.

[0007]

[Means to Solve the Problems]

The present inventors aimed to isolate and identify novel genes with important roles in the development of cardiovascular lesions. Therefore, the inventors initially focused on genes showing enhanced expression at sites of cardiovascular lesion, and especially aimed to isolate genes with locally enhanced expression in the heart by using the subtraction method (see Swaroop *et al.*, Nucleic Acids Res. 19: 1954 (1991)). As a result, a novel gene of approximately 12-kb in full length, whose expression is increased in the heart following the administration of the L-NAME NO synthase inhibitor was isolated by screening a cDNA library. The novel gene obtained was named the LACS (L-NAME-related actin cytoskeletal

protein) gene. Northern blot analysis showed that this gene is expressed in the heart and skeletal muscles. A particularly strong mRNA expression was confirmed in myocardial cells of the heart. Cellular distribution showed co-localization and expression with some of the actin stress fibers. Immunoprecipitation analysis showed that the expressed protein binds (directly or indirectly) to actin fibers, and Western blotting also showed it to be in the skeletal fraction. Furthermore, the amino acid sequence predicted from the nucleotide sequence of this gene was analyzed for its functions, properties, and such, and no characteristic sequences including signal sequences and transmembrane regions were found. However, a proline-rich sequence was present in the C terminus, and this sequence was found to be homologous to an SH3-binding domain.

[0008]

The above-mentioned results, along with the large size of the gene and so on, indicated that LACS is a structural protein related to the cytoskeleton. LACS mRNA was abundantly expressed in a blood-pressure independent manner in the hearts of several model animals with hypertension and cardiomegaly (L-NAME rats, AngII infusion rats, and spontaneously hypertensive rats (SHRs)). In cultured myocardial cells, increased LACS mRNA expression due to hypertrophic agonist stimulation was observed. Furthermore, the expression mechanism was suggested to involve the AngII-AT1R pathway and the Rho/ROCK system. LACS was thought to increase in expression along actin upon hypertrophic stimuli, bind directly or indirectly to actin, and participate in the reorganization of actin fibers through functional modulation of actin. The above-mentioned increase of mRNA expression by angiotensin (AngII), phenylephrine, endothelin-1, and such suggests that at least a portion of LACS expression is regulated by the downstream signaling of the G-protein-coupled receptor.

[0009]

This gene, which is highly expressed in hypertension and cardiomegaly model animals, has increased expression in cultured myocardial cells due to hypertrophic agonist stimulation, and encodes a protein that was suggested to associate with the modulation of actin polymerization, is expected to be used as a pharmaceutical for cardiac diseases such as cardiac failure, cardiomegaly, myocarditis, or cardiomyopathy.

Accordingly, the present invention provides:

(1) A protein selected from (a) to (d):

- (a) a protein comprising the amino acid sequence of SEQ ID NO: 1;
- (b) a protein comprising the amino acid sequence of SEQ ID NO: 1, wherein one or more amino acids have been modified by deletion, substitution, addition, and/or insertion;
- (c) a protein comprising a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID NO:

2; and

(d) a protein comprising an amino acid sequence having 60% homology to the amino acid sequence of SEQ ID NO: 1;

(2) A polynucleotide encoding the protein of claim 1 or a portion thereof;

(3) The polynucleotide of claim 2, which comprises the nucleotide sequence of SEQ ID NO: 2;

(4) A pharmaceutical comprising the protein of claim 1;

(5) The pharmaceutical of claim 4, which is used to prevent, improve, or treat cardiac failure, cardiomegaly, myocarditis, or cardiomyopathy;

(6) A pharmaceutical comprising the polynucleotide of claim 2; and

(7) The pharmaceutical of claim 6, which is used to prevent, improve, or treat cardiac failure, cardiomegaly, myocarditis, or cardiomyopathy.

[0010]

[Mode for Carrying Out the Invention]

The present invention provides the novel gene LACS, which plays an important role in cardiovascular lesions. The nucleotide sequence of the LACS cDNA is shown in SEQ ID NO: 2, the amino acid sequence of the LACS protein predicted from the nucleotide sequence and encoded by the LACS cDNA is shown in SEQ ID NO: 1.

[0011]

The proteins of this invention are proteins comprising the amino acid sequence of SEQ ID NO: 1. These proteins can be obtained, for example, from cells producing these proteins using an affinity chromatography column to which antibodies against the protein are bound. The proteins can also be purified by conventional protein purification techniques based on the molecular weight of the LACS protein (373 kDa) and their binding affinity to actin. Since the expression of LACS protein in cultured myocardial cells can be induced by L-NAME administration, L-NAME-induced LACS protein can be isolated and purified by: salting out; chromatography such as gel filtration chromatography, ion-exchange chromatography, reverse-phase chromatography, affinity chromatography, hydrophobic chromatography, adsorption chromatography, and such; gel electrophoresis; ultrafiltration; re-crystallization; distillation; dialysis; isoelectric focusing; filtration; immunoprecipitation; solvent extraction; solvent precipitation; and such (see, ed. Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Press (1996)).

[0012]

Fusion proteins are included in the proteins comprising the amino acid sequence of SEQ ID NO: 1. Examples of such fusion proteins are: the proteins of this invention to which



a signal sequence instructing host cells to secrete is added for easy purification, when the proteins are expressed by genetic engineering techniques; and those attached with a tag comprising FLAG, histidine residues, or such for easy recovery, or a tag such as GFP for detection. Fusion proteins cleavable by thrombin, Xa factor, or such using conventional techniques can be prepared, and portions other than the portions corresponding to the proteins of this invention can be deleted as necessary.

[0013]

The proteins of this invention can also be proteins comprising an amino acid sequence obtained by modifying the amino acid sequence of SEQ ID NO: 1, through deletion, substitution, addition, and insertion of one or more amino acids. Such proteins can be obtained by modifying and expressing the polynucleotides encoding proteins comprising the amino acid sequence of SEQ ID NO: 1 by commonly used genetic techniques. Genetic modification techniques include, for example, the site-directed mutagenesis method (ed. Ausubel *et al.*, Current Protocols in Molecular Biology, publish. John Wiley & Sons, section 8.1-8.5 (1987)). Such modified proteins can also be used to prepare fusion proteins as described above, as necessary.

[0014]

Furthermore, the proteins of this invention are proteins comprising a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2. Such proteins can be obtained by, for example, preparing probes based on the nucleotide sequence of SEQ ID NO: 2, screening a mammalian cDNA library, genomic library, and such by the hybridization method (ed. Ausubel *et al.*, Current Protocols in Molecular Biology, publish. John Wiley & Sons, section 6.3-6.4 (1987)), and expressing the obtained polynucleotides. However, the phrase “polynucleotide that hybridizes under stringent conditions with the polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2” as used in this invention is not intended to restrict the method for producing such polynucleotides to those obtained by the hybridization method. Therefore, polynucleotides that can be produced by techniques such as the aforementioned site-directed mutagenesis are included in the definition, as long as they hybridize under stringent conditions with the nucleotide sequence of SEQ ID NO: 2. Herein, the term “stringent conditions” refers to conditions of low salt concentration or high temperature in the washing step, and includes conditions of 1x SSC, 0.1% SDS, 37°C (or 55°C).

[0015]

The proteins of this invention include proteins comprising an amino acid sequence homology of 50% or more, preferably 70% or more, more preferably 80% or more, even more preferably 90% or more, and most preferably 95% or more (for example, 96%, 97%, 98%,

99%, or more) to the amino acid sequence of SEQ ID NO: 1. Such proteins can be obtained by the above-mentioned site-directed mutagenesis and hybridization method, PCR method (ed. Ausubel *et al.*, Current Protocols in Molecular Biology, publish. John Wiley & Sons, section 6.1-6.4 (1987)), and such. The homologies in this invention are determined using the  
5 BLAST algorithm (Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90: 5873-7 (1993)). Programs such as BLASTX (Altschul *et al.*, J. Mol. Biol. 215: 403-10 (1990)) that have been developed based on the BLAST algorithm are known. One can refer to  
“<http://www.ncbi.nlm.nih.gov>.” for the specific analytical procedures.

[0016]

10 The LACS protein of this invention is highly expressed in the hearts of several hypertension and cardiomegaly model animals, and is encoded by a gene whose expression increases locally in the heart upon administration of the L-NAME NO synthase inhibitor. Therefore, the protein expression can be used as a basis for detecting the inhibition of NOS  
15 expression or activity. Detection of the protein expression is not limited thereto, and can be done using antibodies against the protein. An Antibody against a protein of this invention can be produced by conventional techniques using apparently the protein comprising the amino acid sequence of SEQ ID NO: 1, or a portion thereof, or using an above-mentioned  
20 protein of this invention that has the antigenicity of the protein comprising the amino acid sequence of SEQ ID NO: 1. Therefore, the proteins of this invention and peptide fragments thereof can be used to produce antibodies that enable the diagnosis of diseases induced by decreased NOS expression or activity. When the proteins of this invention are used as  
pharmaceuticals for humans, human-derived LACS protein is preferably used, but is not limited thereto. Human-derived LACS protein can be obtained by generating probes or  
25 primers based on the sequence information of the LACS protein and gene of this invention, obtaining a gene encoding the desired protein using the above-mentioned hybridization method or various PCR methods, and expressing this gene.

[0017]

30 The proteins of this invention include proteins that are functionally equivalent to the proteins comprising the amino acid sequence of SEQ ID NO: 1. Herein, the phrase “functionally equivalent to the proteins comprising the amino acid sequence of SEQ ID NO: 1” refers to having the activity to enhance or suppress the polymerization, crosslinking, or  
bundle formation of actin. Proteins functionally equivalent to the LACS protein comprising the amino acid sequence of SEQ ID NO: 1 also include proteins that can be obtained by using  
35 the above-mentioned site-directed mutagenesis method, hybridization method, PCR method, and such.

[0018]

Furthermore, the present invention provides polynucleotides that encode the proteins of this invention, or portions thereof. Such polynucleotides include cDNAs, genomic DNAs, mRNAs, and chemically synthesized DNAs and RNAs. A single protein of the present invention can be encoded by a plurality of polynucleotides due to the degeneracy of the genetic code. Thus, the polynucleotides of this invention also include such degenerate polynucleotides. Naturally occurring polynucleotides of this invention can be obtained by, for example, generating probes, primers, and such based on the entire or a portion of the nucleotide sequence encoding the LACS protein of this invention comprising SEQ ID NO: 2, and performing well-known techniques such as hybridization and PCR. Furthermore, if necessary, the obtained polynucleotides can be modified by, for example, restriction enzyme digestion, site-directed mutagenesis, or addition of a suitable fragment (including linkers, initiation codons and stop codons), linked to a polynucleotide encoding a different polypeptide for fusion protein expression, or integrated into an appropriate vector (expression vectors, cloning vectors, and such). The polynucleotides of this invention also include these polynucleotides.

[0019]

The present invention also provides polynucleotides comprising at least 13 consecutive nucleotides complementary to the nucleotide sequence of SEQ ID NO: 2 or its complementary strand. Such complementary polynucleotides do not have to be completely complementary to the nucleotide sequence of SEQ ID NO: 2 or its complementary strand, as long as they have homologies of at least 70% or higher, preferably 80% or higher, more preferably 90% or higher, and even more preferably 95% or higher. Homology can be determined according to the aforementioned methods. Such polynucleotides can be used as probes or primers for the detection and amplification of DNAs and mRNAs encoding the proteins of this invention. When the polynucleotides are used as primers, restriction enzyme recognition sequences and/or tags, for example, can be added to their 5' ends as necessary. The polynucleotides may also be used as antisense nucleotides, ribozymes, and such. Antisense nucleotides and ribozymes can be used for inhibiting or suppressing the expression of the proteins of this invention.

[0020]

The proteins of this invention can be obtained by integrating the polynucleotides of this invention into appropriate expression vectors under the control of an expression regulatory region comprising enhancers, promoters, and such, and introducing the vectors into appropriate host cells. Examples of the host cells are prokaryotic cells and eukaryotic cells. For eukaryotic cells, systems using *E. coli* are well known. Examples of the promoters used

when the host is *E. coli* are lacZ promoter (Ward *et al.*, Nature 341: 544-6 (1998)), and ara promoter (Better *et al.*, Science 240: 1041-3 (1988)). When *E. coli* is used as a host to produce the proteins of this invention by genetic engineering methods, attachment of a signal sequence that enables the production of proteins into the periplasm is desired for easy purification. An example of the signal sequence is pelB signal sequence (Lei *et al.*, J. Bacteriol. 169: 4379 (1987)). The expression vectors for *E. coli* may further include the replication origins derived from SV40, polyomavirus, adenovirus, bovine papillomavirus, and such, and selection markers such as aminoglycoside transferase gene, thymidine kinase gene, xanthine guanine phosphoribosyl transferase gene, and dihydrofolate reductase gene. In addition to *E. coli*, prokaryotic expression systems using *Bacillus subtilis* as the host are well known.

[0021]

For eukaryotic hosts, yeast cell systems, plant cell systems, and animal cell systems including insect cells, amphibian cells, and mammalian cells are known. Generally used yeast cell systems include systems that use a *Saccharomyces* yeast or an *Aspergillus* mold as host. For plant cell systems, those that use *Nicotiana tabacum* cells as hosts are known. In plant cell systems, proteins can be produced in callus cultures, or obtained by regenerating plants from cells transfected with the desired gene and obtaining the proteins of interest from the leaves, roots, stems, and such of the plants (Julian *et al.*, Eur. J. Immunol. 23: 131-8 (1994)). Examples of the mammalian cells include BHK, CHO, COS, HeLa, myeloma, and 3T3. *Xenopus* oocytes (Valle *et al.*, Nature 291: 358-40 (1981)) are known as amphibian cells while Sf9, Sf21, Tn5, and such are well-known insect cells. The constructed vectors are introduced into host cells by well-known methods such as the calcium phosphate method (Virology 52: 456-67 (1973)), and electroporation method (EMBO J. 1: 841-5 (1982)).

[0022]

The proteins of this invention can also be produced *in vivo* using animals (see Lubon, Biotechnol. Annu. Rev. 4: 1-54 (1998)). Examples of the animals are: domestic animals such as cattle, sheep, pigs, and goats (Ebert *et al.*, Bio/Technology 12: 699-702 (1994)); mammals such as mice; insects such as silkworms. For the production of an exogenous protein in mammals, a DNA encoding the protein of interest is fused with a gene encoding a protein specifically secreted in milk, such as  $\beta$ -casein. Next, the fusion gene is injected into the embryo of the animal to induce chromosomal recombination. The protein of interest can be obtained from the milk produced by the transgenic animals (i.e., those born as a result of transplanting this embryo transplanted into the uterus of a female animal) or from their offspring. Alternatively, when silkworms are used, baculovirus that carries an integrated gene encoding the desired protein is used to infect silkworms, and the desired protein can be

obtained from the silkworm body fluids (Susumu *et al.*, Nature 315: 592-4 (1985)).

[0023]

Proteins that have been secreted inside or from host cells as a result of genetic engineering can be purified by the same method as for the naturally occurring proteins. For proteins that have been optionally modified for the convenience of purification, the modified peptide portions can be removed by reacting with an appropriate protein modification enzyme before or after protein purification.

[0024]

Antibodies against the proteins of this invention can be obtained using the proteins of this invention, or portions thereof. The antibodies in this description include polyclonal antibodies, monoclonal antibodies (Milstein *et al.*, Nature 305: 537-40 (1983)), and antibody fragments. A polyclonal antibody against a protein of this invention may be, for example, serum obtained from the blood of a mammal sensitized with an antigenic portion of a protein of this invention. This serum can be further purified to prepare fractions comprising the polyclonal antibody. On the other hand, monoclonal antibodies can be prepared using the hybridoma method (Kohler and Milstein, Nature 256: 495 (1975)), by collecting immunocytes from mammals sensitized with an antigen; cloning hybridomas by fusing the collected cells with cells capable of permanent proliferation, such as myeloma cells; collecting monoclonal antibodies from the culture.

[0025]

Antibody fragments refer to fragments comprising the antigen-binding region or variable region of an antibody, and include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments and such. Fab is a fragment obtained by papain digestion of antibody molecules. Pepsin digestion of an antibody yields the F(ab')<sub>2</sub> fragment. As for other antibody fragments, examples include diabodies (Holliner *et al.*, Proc. Natl. Acad. Sci. USA 90: 6444-8 (1993)), filamentous antibodies, single chain antibodies such as scFV (Plucktun, "The Pharmacology of Monoclonal Antibody", Vol. 113, ed. Rosenberg and Moore, Springer Verlag, pp.269-315 (1994)), and multispecific antibodies (LeDoussal *et al.*, Int. J. Cancer Suppl. 7: 58-62 (1992); Paulus, Behring Inst. Mitt. 78: 118-32 (1985); Millstein and Cuello, Nature 305: 537-9 (1983); Zimmermann, Rev. Physiol. Biochem. Pharmacol. 105: 176-260 (1986); Van Dijk *et al.*, Int. J. Cancer 43: 944-9 (1989)). Furthermore, the antibodies of this invention can be modified by molecules such as polyethylene glycol. The antibodies thus obtained can be purified by methods similar to those for purifying other proteins (ed. Harlow and David Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988)).

[0026]

Since the proteins of this invention are expressed specifically in myocardial cells, and

increase in diseased conditions such as left ventricular hypertrophy, they may be used to prevent, improve, or treat cardiac diseases such as cardiac failure, cardiomegaly, myocarditis, or cardiomyopathy. Therefore, by enhancing or regulating the functions of the proteins of this invention, these proteins can be formulated as agents to prevent, improve, or treat these cardiac diseases. When the proteins are used as pharmaceuticals, they can be administered to a patient directly and on their own, or formulated using conventional formulation methods. Examples of such methods include dissolving into a neutral solution such as PBS. Furthermore, pharmaceutically acceptable stabilizers, buffers, sweeteners, diluents, corrigents, fillers, coloring agents, emulsifiers, excipients, disintegrating agents, flavoring agents, preservatives, solubilizers, and such may be added as necessary. By combining with carriers, the proteins of this invention can be prepared into forms such as solutions, elixirs, capsules, granules, pills, suspensions, powders, tablets, syrup, injections, troches, and emulsions.

[0027]

The dosage of the pharmaceuticals comprising the proteins of this invention depends on a number of factors such as the weight, age, and symptoms of the patient, as well as the method and form of administration. One skilled in the art can determine the appropriate dosage. The pharmaceuticals can be, for example, administered subcutaneously or orally, or administered by intraarterial or intravenous injection. The daily protein dosage for adults (body weight of 60 kg) is normally 1  $\mu$ g to 10 g, preferably 10  $\mu$ g to 1 g, and more preferably 100  $\mu$ g to 100 mg. Furthermore, the dosage can be calculated based on the body weight when administering into animals other than humans.

[0028]

Instead of the proteins of this invention, polynucleotides encoding these proteins may be used as pharmaceuticals. Similarly to pharmaceuticals comprising the proteins of this invention, pharmaceuticals comprising such a gene as an active ingredient can be used to prevent, improve, or treat cardiac diseases such as cardiac failure, cardiomegaly, myocarditis, cardiomyopathy, arteriosclerosis, arteriosclerosis obliterans, or ischemic heart disease. Hereinafter, methods, forms, and amounts of gene transfer will be described specifically for gene therapies using the polynucleotides of this invention.

[0029]

Methods for administering gene therapy agents comprising a LACS gene as an active ingredient can be classified into two groups: methods using non-viral vectors and methods using viral vectors. The preparation methods, administration methods, and such for these vectors are described in detail in experiment manuals (Jikken Igaku (Experimental Medicine) Supplementary Volume, "Idenshichiryō no Kisogijyutsu (Fundamental Techniques for Gene Therapy)", Yodosha, 1996; Jikken Igaku (Experimental Medicine) Supplementary Volume,

“Idenshidonyu & Hatsugenkaiseki Jikkenho (Experimental Methods for Gene Transfer & Expression Analysis)”, Yodosha, 1997; “Idenshi-chiryō Kaihatsu Kenkyū Handbook (Handbook of Gene Therapy Research and Development)”, Nihon Idenshichiryō Gakkai (The Japan Society of Gene Therapy) Edition, NTS, 1999).

5 [0030]

The target gene can be introduced into cells or tissues by using the methods below and a recombinant vector prepared by inserting a target gene into a conventional non-viral gene expression vector. Examples of methods for transferring genes into cells are: lipofection methods, calcium-phosphate co-precipitation methods, DEAE-dextran methods, 10 methods that directly infuse DNA using a glass capillary tube, etc. Methods for transferring genes into tissues include methods using virus envelope vectors, internal type liposomes, electrostatic type liposomes, HVJ-liposomes, improved type HVJ-liposomes (HVJ-AVE liposomes), receptor-mediated gene transfer methods, methods for transferring carriers (such as metal particles) along with DNAs using particle guns, methods for directly introducing 15 naked-DNAs, introduction methods using positively charged polymers, etc.

[0031]

The aforementioned HVJ-liposomes are constructed by incorporating a DNA into a liposome formed by a lipid bilayer, then fusing this liposome with an inactivated Sendai virus (hemagglutinating virus of Japan; HVJ). The use of HVJ-liposomes is characterized by 20 extremely high cell membrane fusion compared to conventional liposome methods, and is one of the especially preferred forms of introduction. Methods for preparing HVJ-liposomes are described in detail in, for example, Experimental Medicine Supplementary Volume, “Idenshichiryō no Kisogijyutsu (Fundamental Techniques of Gene Therapy)”, Yodosha, 1996; Experimental Medicine Supplementary Volume, “Idenshidonyu & Hatsugenkaiseki Jikkenho (Experimental Methods for Gene Transfer & Expression Analysis)”, Yodosha (1997); J. Clin. Invest. 93: 1458-64 (1994); Am. J. Physiol. 271: R1212-20 (1996). Methods for using the HVJ-liposome are described in, for example, Molecular Medicine 30: 1440-8 (1993); Jikken Igaku (Experimental Medicine), 12: 1822-6 (1994); and Tanpakushitsu Kakusan Kouso (Protein, Nucleic Acid, and Enzyme), 42: 1806-13 (1997); and a more preferable method is 30 described in Circulation 92 (Suppl. II): 479-82 (1995).

[0032]

Furthermore, methods using viral envelopes are particularly preferable when administering a LACS gene of this invention. Viral envelopes can be prepared by mixing a purified virus with an expression vector of interest in the presence of a surfactant, or by 35 freezing and thawing a mixture of a virus and an expression vector (JP-A 2001-286282).

[0033]

The viruses that can be used in the viral envelope methods are viruses belonging to families such as the retrovirus, togavirus, coronavirus, flavivirus, paramyxovirus, orthomyxovirus, bunyavirus, rhabdovirus, poxvirus, herpesvirus, baculovirus, and hepadnavirus families, and HVJs are particularly preferable. Herein, these viruses can be  
5 either wild-type or recombinant viruses. In particular, a recombinant HVJ reported by Hasan, M. K. *et al.* (J. General Virol. 78: 2813-20 (1997)), Yonemitsu, Y. *et al.* (Nature Biotech. 18: 970-3 (2000)), or such may be used as an HVJ.

[0034]

While the Z strain (available from ATCC) of HVJ is generally preferable in methods  
10 using HVJ-liposomes or HVJ-envelopes, fundamentally, other HVJ strains (for example, ATCC VR-907 and ATCC VR-105) can also be used. When preparing a viral envelope, purified viruses can be inactivated by UV irradiation and such, and mixed with a desired expression vector. Surfactants that can be used for mixing the virus and expression vector include, for example, octylglucoside, Triton X-100, CHAPS, and NP-40. Viral envelope  
15 vectors prepared in this manner can be introduced by injection or such into tissues to be targeted for therapy, prevention, or remedy. Furthermore, by freezing at -20°C the viral envelope vectors can be stored for at least two to three months.

[0035]

Any expression vector may be used here as long as they can express a target gene *in*  
20 *vivo*. Examples of the expression vectors are pCAGGS (Gene 108: 193-200 (1991)), pBK-CMV, pcDNA3.1 (Invitrogen), and pZeoSV (Stratagene).

[0036]

Representative methods for gene transfer with viral vectors are those methods using viral vectors such as recombinant adenoviruses and retroviruses. More specifically, a target  
25 gene can be transferred into cells by the steps of: introducing the gene into DNA or RNA viruses such as detoxicated retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, lentiviruses, vaccinia viruses, poxviruses, polioviruses, sindbis viruses, Sendai viruses, SV40, or human immunodeficiency viruses (HIV) (see Pharmacol. Ther. 80: 35-47 (1998); Front. Biosci. 4: E26-33 (1999); J. Recep. Signal. Transduct. Res. 19: 673-86); and then infecting  
30 cells with the resultant recombinant virus. The infection efficiency of adenovirus vectors is much greater than the other aforementioned viral vectors. Thus, from this viewpoint, the use of an adenovirus vector system is preferred.

[0037]

Methods for introducing an agent of the present invention to a patient during gene  
35 therapy include: the *in vivo* introduction of a gene therapy agent directly into the body; and the *ex vivo* introduction of a gene therapy agent into a cell harvested from the patient, followed by



reintroduction of the modified cell into the body (Nikkei Science, April 1994, 20-45; Gekkann Yakuji 36 (1), 23-48, 1994; Jikken Igaku (Experimental Medicine) Supplementary Volume, 12 (15), 1994; "Idenshi-chiryō Kaihatsu Kenkyū Handbook (Handbook of Gene Therapy Research and Development)", Nihon Idenshichiryō Gakkai eds. (The Japan Society of Gene Therapy) Edition, NTS, 1999). *In vivo* methods are particularly preferred in the present invention.

[0038]

Various formulations, (for example, liquid preparations), suited for each of the above-mentioned administration methods may be adopted as the form of preparation. For example, an injection comprising a gene as an active ingredient can be prepared by conventional methods, which might include dissolving a gene in an appropriate solvent (e.g., a buffer solution, such as PBS, physiological saline, and sterilized water), sterilizing by filtration as necessary, and then loading into a sterile container. Conventional carriers or such may be added to injection agents as required. Alternatively, liposome preparations, such as preparations comprising HVJ-liposome, can be prepared as suspensions, frozen agents, or centrifugally concentrated frozen agents.

[0039]

The dosage of the pharmaceuticals comprising the polynucleotides of this invention depends on a number of factors such as the weight, age, and symptoms of the patients, as well as on the method and form of administration. One skilled in the art can determine the appropriate dose. The pharmaceuticals can be, for example, administered subcutaneously or orally, or by intraarterial or intravenous injection. The daily polynucleotide dosage for adults (body weight of 60 kg) is normally 1  $\mu$ g to 10 g, preferably 10  $\mu$ g to 1 g, and more preferably 100  $\mu$ g to 100 mg. Furthermore, the dosage can be calculated based on the body weight when administering to animals other than humans.

More specifically, since the polynucleotides of this invention can be repeatedly administered when using the HVJ-envelope method, the gene is administered a number of times, for example, twice or three times, but not all together at once, in order to obtain better therapeutic, preventive, or improvement effects. The present invention also includes such types of administration which are performed over a number of times using the HVJ envelope.

[0040]

The appropriate administration methods and sites to be administered for the pharmaceuticals comprising the proteins or polynucleotides of this invention are selected according to the disease and symptoms to be treated. The preferred administration method is intramyocardial or intramuscular administration, but is not limited thereto.

[0041]

Since the LACS gene of this invention was found to increase in the heart of several hypertension and cardiomegaly model animals, it can be used to diagnose the presence or absence of hypertension and cardiomegaly in patients. Such diagnoses may be performed by detecting intracellular mRNAs transcribed from the gene, using probes or primers generated  
5 based on the sequence information of the LACS gene of this invention. Extraction of mRNAs from biological samples can be also performed using a commercially available kit (such as the mRNA Purification Kit (Pharmacia) and QuickPrep mRNA Purification Kit (Pharmacia)). In addition, methods for preparing total RNAs, such as guanidine ultracentrifugation methods (Chirgwin *et al.*, Biochemistry 18: 5294-9 (1979)) and AGPC  
10 methods (Chomczynski and Sacchi, Anal. Biochem. 162: 156-9 (1987)), are well known. Meanwhile, methods for detecting proteins expressed from these genes using antibodies against the proteins of this invention may also be considered. When examining the indicator gene expression in cells, its expression level is usually corrected with the measured expression levels of genes whose expression levels do not vary substantially with the cellular condition  
15 (housekeeping genes such as  $\beta$ -actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are often used).

[0042]

The LACS protein and the LACS gene of this invention can be used to screen for compounds useful as pharmaceuticals for cardiovascular diseases. As indicated in the  
20 present invention, *in vivo* expression of the LACS protein increases in response to the administration of NO synthetic inhibitors or hypertrophic agonists. Therefore, compounds that bind to the LACS protein may be candidates of pharmaceuticals for cardiovascular diseases. Such compounds can be screened, for example, by the steps of:

- (1) contacting a test compound with a proteins of this invention or a partial peptide thereof;
- 25 (2) detecting the binding of the test compound to the protein, or partial peptide; and
- (3) selecting a test compound that binds to the protein, or the partial peptide.

Alternatively, binding of test compounds to proteins of this invention can be investigated by contacting test compounds with host cells that maintain the expression of polynucleotides encoding the proteins of this invention, or with a host cell culture, instead of  
30 the proteins of this invention or partial peptides thereof in step (1).

[0043]

In the present invention, the LACS protein was shown to bind to actin. By inhibiting the binding between the LACS protein and actin, actin polymerization may be enhanced or suppressed. Therefore, compounds that inhibit the binding between the LACS  
35 protein and actin may be candidates of pharmaceuticals for cardiovascular diseases. Methods for screening compounds that inhibit the binding of the LACS protein can be performed using

the binding between the protein and actin as an index. More specifically, such compounds can be screened, for example, by the steps of:

- (1) contacting a test compound with a protein of this invention or a partial peptide thereof in the presence of actin;
- 5 (2) detecting the binding of actin to the protein or partial peptide; and
- (3) selecting a test compound that suppresses or inhibits the binding of actin to the protein or partial peptide.

The partial peptides used here must comprise the portion(s) involved in the binding between the LACS protein and actin. Such partial peptides can be obtained easily by analyzing the  
10 actin affinity of the various fragments produced upon digestion of the LACS protein.

Furthermore, binding between the LACS protein and actin may be carried out by methods as described in Example 7, using LACS antibodies and actin antibodies, but is not limited thereto.

[0044]

15 The present invention also provides methods of screening for compounds that regulate the expression of the proteins of this invention. Compounds that enhance or suppress the expression of the LACS protein may be candidates of pharmaceuticals for cardiovascular diseases. Such screening can be performed using myocardial cells and smooth muscle cells expressing the LACS gene by the steps of:

- 20 (1) contacting a test compound with cells expressing the LACS gene;
- (2) detecting the expression of LACS gene; and
- (3) selecting a test compound that enhances or suppresses the expression of the LACS gene compared to when the test compound is absent.

Various cells including *E. coli*, yeast, insect cells, plant cells, oocytes, and  
25 mammalian cells can be used for the expression of the LACS gene. Similarly to the detection of the *in vivo* expression of LACS gene in patients, transcribed mRNAs and proteins can be detected according to conventional methods.

[0045]

Furthermore, cells that have been transformed with an expression vector, in which a  
30 reporter gene is operably linked to an expression regulatory sequence upstream of the LACS gene, can be used in place of cells that express the LACS gene. Examples of the upstream expression regulatory sequence of the LACS gene are promoters, enhancers, CAAT box, and TATA box. For example, probes are generated based on the nucleotide sequence of SEQ ID NO: 2, and genomic DNA clones comprising the expression regulatory sequence of the LACS  
35 gene is obtained by screening a genomic DNA library. The expression regulatory sequence portion of this clone is excised by restriction enzyme treatment, and then cloned to be operably

linked to the upstream of an appropriate reporter gene. Examples of the reporter gene are chloramphenicol acetyltransferase (CAT) gene, lacZ gene, luciferase gene, green fluorescent protein (GFP) gene, and growth hormone gene. The obtained construct in which a reporter gene is linked downstream of the LACS gene expression regulatory sequence is introduced  
5 into an appropriate host cell (preferably mammalian cells) by any one of the above-described methods. When this construct is intended for the insertion into the host cell chromosome, homologous recombination techniques may be used.

[0046]

Expression of the reporter gene is detected by methods appropriate for the type of  
10 reporter gene employed. For example, the level of CAT gene expression is determined by the detection of chloramphenicol acetylation due to the gene expression product. When using the lacZ gene, the coloring catalysis of the coloring compound in the gene expression product is measured as an indicator of the expression level of the gene. When the reporter gene is the  
15 luciferase gene, fluorescence of a fluorescent compound that results from the catalysis of the gene expression product is detected and this can be used as an indicator of expression level. Since GFP protein emits fluorescence, when the GFP gene is used as the reporter gene, the expression level is determined according to the fluorescence level of the expression product. When using the growth hormone gene, the effects (growth stimulation, proliferative  
20 stimulation, and such) of the gene expression product on cells are examined and the expression level is quantified.

[0047]

Examples of test compounds to be used in each of the above-mentioned screening methods include naturally occurring compounds, synthetic compounds, inorganic compounds,  
25 organic compounds, and proteins, peptides, and non-peptide compounds that are crude, purified or partially purified. In addition, compound libraries comprising a plurality of compounds, expression products derived from a gene library, cell extracts, cell culture supernatants, products of luminescent microorganisms, extracts of marine organisms, plant  
30 extracts, biological tissue extracts, and such may also be used. Proteins or peptides can be used as test compounds by binding with a carrier, fusing with another polypeptide, or expressing on a cell membrane and preparing membrane fractions. These test compounds can be labeled with radiolabeling, fluorescence labeling, and such, as necessary.

[0048]

Cells, expression vectors, test compounds, probes, primers, antibodies, substrates for measuring reporter gene expression, and such, which are necessary for each of the  
35 above-mentioned screening methods, can be appropriately combined into kits. Furthermore, the kits may include, as necessary, media and containers for cell culturing, control samples, kit

instructions, and such. Test compounds selected by the above-mentioned screening can be made into pharmaceuticals to be used directly on patients by themselves, but they may also be formulated and used according to conventional formulation methods, as necessary. When the compounds are polynucleotides such as DNAs, or polypeptides that can be encoded by DNAs, the polynucleotides may be administered according to the aforementioned gene therapeutic methods.

[0049]

[Examples]

Hereinafter, the present invention will be specifically described using Examples, but it is not to be construed as being limited thereto.

[Example 1] Gene isolation by Subtractive Hybridization (SSH)

RNAs were extracted from the hearts of a male WKY rat group that has been subjected to a one-week oral administration of L-NAME (100 mg/L), and from the hearts of a control group without L-NAME administration. The obtained RNAs were used to clone cDNAs that showed enhanced expression in the L-NAME-administered group using the subtraction method. As a result, a novel LACS (L-NAME related actin cytoskeletal protein) gene was successfully isolated. Northern blotting was used to analyze the mRNA expression of this gene in cardiac tissues, and showed that the expression level reaches its peak one to three days after L-NAME administration, begins declining from the seventh day, and gradually decreases to nearly the baseline 28 days after administration. Furthermore, mRNA expression in tissues other than the heart was also analyzed by Northern blotting. The LACS mRNA expression was observed in the heart and skeletal muscles. Particularly with the heart, the expression of LACS mRNA was confirmed in the myocardial cells.

[0050]

[Example 2] Isolation of full-length cDNA

A cDNA library was constructed, and a full-length cDNA encoding LACS was isolated by screening. More specifically, poly RNAs obtained from WKY rats on the first day of L-NAME administration were used to construct a  $\lambda$ ZAPII cDNA library using random primers. Next, by repeated screening using the LACS gene fragments as probes, an approximately 12-kb cDNA in full length was obtained as the LACS gene. Sequencing of this cDNA was performed using the ABI PRISM310 DNA Sequencer (ABI/ Perkin Elmer). The obtained nucleotide sequence is shown in SEQ ID NO: 1. Characteristic sequences such as signal sequences or transmembrane regions could not be found in the amino acid sequence (SEQ ID NO: 2) predicted from the nucleotide sequence. Therefore, it was difficult to

predict the properties and functions of LACS from the sequence alone. However, a proline-rich sequence exists at the C terminus of the predicted amino acid sequence, suggesting an SH3-binding domain homology. SH3 is a homologous portion of approximately 70 amino acids seen in the Src kinase family. The SH3-binding domain is a proline-rich sequence of approximately ten amino acids.

[0051]

[Example 3] mRNA expression in the hearts of hypertension models

Cardiac tissues derived from AngII infusion rats (osmotic pump: 0.7 mg/kg/day), and SHR of 4 weeks and 24 weeks, were used. AT1R antagonist (ARB) and hydrazine (Hyd) were used as antihypertensive agents. Each of the antihypertensive agents was used at an amount sufficient for lowering the blood pressure (10 mg/kg/day for ARB; 12 mg/kg/day for Hyd).

The results present a trend of increased LACS expression after the third day of AngII administration, and decreased expression after the seventh day in the AngII infusion rats. Most of this increase in expression tended to be suppressed by a simultaneous ARB administration, but not by the simultaneous administration of hydrazine. However in SHR, a significant increase of LACS mRNA expression was observed in adult rats that had developed hypertension with progressing cardiomegaly, but not in juvenile rats that had not yet developed hypertension.

As described above, increase of LACS mRNA expression was observed in the hearts of several hypertension and cardiomegaly model animals, and even the correction of hypertension did not completely suppress this expression. These findings suggest the possibility that the LACS mRNA expression is amplified by local activation of the RAS system. Therefore, cellular response to AngII stimulation was examined in Example 6.

[0052]

[Example 4] Localization of the LACS protein

The C-terminal portion of LACS was used to prepare an antibody against LACS. Intracellular localization of LACS was examined by cellular staining using the peptide antibody.

(1) Localization in the heart

LACS was stained in the cardiac tissue in a band pattern, which appeared to be consistent with the intercalated discs. Double staining with cadherin, a representative protein that exists in the intercalated discs, and observation using a confocal fluorescence microscope

showed that LACS localization virtually matched with that of cadherin. Thus, LACS seemed to exist near the intercalated discs.

## (2) Localization in cultured myocardial cells

Primary cultures of myocardial cells isolated from neonatal rats (one- to three-day old) using trypsin and collagenase were prepared. For the first 24 to 48 hours, the cells were cultured in a serum-containing medium, and then for another 24 hours in a serum-free medium.

Western blot analysis of the cultured myocardial cells showed that the LACS protein was fractionated into the cytoskeletal component (TritonX insoluble fraction). In immunostaining, staining along the actin fibers, particularly near the sites of intercellular adhesion, was observed. The sites of intercellular adhesion are said to have an *in vivo* intercalated disc-like structure, and thus LACS was considered to exist along the actin fibers at the sites of intercellular adhesion.

These results showed that LACS is a cytoskeletal protein.

[0053]

### [Example 5] LACS expression

A c-myc tag was attached to LACS, and this construct was inserted into expression vectors, pcDNA3.1 (Invitrogen) and pEGFP (CLONTECH). The obtained expression vectors were transfected into COS-1 cells using FuGene6 (Roche Diagnostics) for transient overexpression. After 48 hours, an approximately 374-kDa band, corresponding to the molecular weight predicted theoretically from the LACS nucleotide sequence, was detected by Western blotting against c-myc. Furthermore, the expression of c-myc-fused LACS protein at the cellular level was confirmed by c-myc immunostaining after immobilizing the cells.

[0054]

### [Example 6] LACS expression increases due to hypertrophic agonist stimulation on cultured myocardial cells

Myocardial cells cultured by the same method in Example 4 were used. First, cells were stimulated with the representative hypertrophic agonists, AngII, phenylephrine, and Endothelin-1. LACS protein expression was detected in each of the cultured cells, and was found to increase when any of the hypertrophic agonists was used.

LACS expression which increases upon phenylephrine stimulation was suppressed by the simultaneous administration of 10  $\mu$ M of Y27632 (ROCK inhibitor; Calbiochem). This suggests that the Rho/ROCK system is related to the expression of LACS gene. Rho is a

low-molecular-weight GTP-binding protein (small G protein) involved in the contraction of smooth muscles, and regulation of cytokinesis, cell motility, and cytomorphology, via reorganization of actin filaments.

5 [0055]

[Example 7] Detection of actin

Immunoprecipitation was performed using the LACS antibody to obtain precipitated proteins from cultured myocardial cells. A band corresponding to the actin protein was detected by Western blotting using an anti-actin antibody.

10 This result shows that LACS and actin bind to each other. Immunostaining in Example 4 suggests the possibility of LACS interacting with cadherin since its localization matches that of cadherin. However, a band corresponding to cadherin was not detected in the above-mentioned experiment, and therefore the possibility of direct binding to cadherin was rejected.

15

[0056]

[Example 8] LACS expression in the carotid arteries

Analysis of LACS mRNA expression by RT-PCR confirmed its expression in the carotid arteries. After balloon injury, mRNA expression gradually increased and peaked on  
20 the seventh day. This suggests the possibility that LACS exists in the smooth muscles. Since smooth muscles are stable and readily cultured, they are convenient for further functional analyses of LACS.

[0057]

25 [Effects of the Invention]

The present invention provides novel actin-related cytoskeletal protein LACS and genes encoding this protein. The present invention reveals that: the expression of the LACS protein is increased in the heart of several hypertension and cardiomegaly model animals; this expression increases when hypertrophic agonists are administered; and the LACS protein is  
30 bound to actin in cells. These facts suggest that the LACS protein plays a specific role in the maintenance of the cardiovascular system by enhancing or suppressing actin polymerization. Therefore, the proteins of this invention and polynucleotides encoding these proteins may be effective for the prevention, improvement, or treatment of cardiac diseases involving actin polymerization, such as cardiac failure, cardiomegaly, myocarditis, cardiomyopathy,  
35 arteriosclerosis, arteriosclerosis obliterans, and ischemic heart disease.



[0058]

[Sequence Listing]

SEQUENCE LISTING

5 &lt;110&gt; AnGes MG, Inc.

&lt;120&gt; Novel actin-related sytoskeletal protein LACS

&lt;130&gt; MED-A0206

10

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 2

15

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 3302

20

&lt;212&gt; PRT

&lt;213&gt; Rattus rattus

&lt;400&gt; 1

Met Ala Arg Tyr Gln Ala Ala Val Ser Arg Gly Asp Thr Arg Ser Phe

25

1

5

10

15

Ser Ala Asn Val Met Glu Glu Ser Asp Leu Ser Thr Val Pro Gly Gly

20

25

30

30

Leu Ala Lys Met Lys Arg Gln Phe Glu Lys Asp Glu Met Thr Ser Thr

35

40

45

Cys Asn Ala Phe Ser Glu Tyr Gln Tyr Gln His Glu Ser Arg Ser Glu

50

55

60

35

Gln Glu Ala Ile His Asn Arg Gln Glu Ile Arg Arg Asn Glu Glu Glu

	65		70		75		80									
	Val	Ser	Lys	Gly	His	Arg	Thr	Asp	Val	Phe	Lys	Ala	Glu	Met	Met	Ser
					85					90					95	
5	His	Leu	Glu	Lys	His	Thr	Glu	Glu	Thr	Asn	Gln	Ala	Ser	Gln	Phe	Arg
				100					105					110		
	Gln	Tyr	Val	Gln	Glu	Thr	Val	Ile	Asp	Thr	Pro	Glu	Asp	Glu	Glu	Ile
10		115					120					125				
	Pro	Lys	Val	Ser	Thr	Lys	Ile	Leu	Lys	Glu	Gln	Phe	Glu	Lys	Thr	Ala
		130				135						140				
15	Gln	Glu	Asn	Phe	Leu	Tyr	Ser	Asp	Lys	Glu	Thr	Thr	Thr	Pro	Ala	Lys
	145				150					155				160		
	Cys	Ile	Lys	Ile	Glu	Asn	Asp	Ser	Glu	Glu	Thr	Leu	Lys	Pro	Ser	Ser
				165						170				175		
20	Ala	Met	Gly	Thr	Ser	Ser	Tyr	Thr	Ser	Ala	Arg	Gln	Ser	Lys	Glu	Thr
				180						185				190		
	Ser	Thr	Ser	Ser	Tyr	Ser	Asn	His	Ser	Leu	Thr	Ser	Thr	Ile	Leu	Ala
25		195					200					205				
	Gln	Glu	Lys	Gly	Thr	Pro	Ser	Gly	Lys	Met	Glu	Glu	Phe	Pro	Pro	Pro
		210					215					220				
30	Pro	Pro	Asp	Val	Phe	Gln	Thr	Pro	Met	Asp	Val	Thr	Ala	Phe	Ser	Gln
	225				230					235				240		
	Ser	Pro	Glu	Phe	Pro	Ser	Pro	Pro	Arg	Arg	Leu	Pro	Met	Pro	Arg	Asp
				245					250				255			
35	Val	Tyr	Ser	Lys	Gln	Arg	Asn	Leu	Tyr	Glu	Leu	Asn	Arg	Leu	Tyr	Arg

	260	265	270
	His Ile His Pro Glu Leu Arg Lys Asn Leu Glu Lys Asp Tyr Ile Ser		
	275	280	285
5	Glu Val Ser Glu Ile Val Ser Ser His Ile Asn Ser Gly Asn Ser Ile		
	290	295	300
	Ser Ala Gly Val Gln Gln Ala Arg Tyr Val Phe Glu Asn Thr Asn Asp		
10	305	310	315 320
	Ser Ser Gln Lys Asp Leu Ser Ser Glu Arg Glu Asn Leu Glu Trp Asp		
	325	330	335
15	Glu Ile Leu Lys Gly Glu Val Gln Ser Ile Arg Trp Ile Phe Glu Asn		
	340	345	350
	Gln Pro Leu Asp Ser Ile Asn Gln Gly Phe Thr Asp Glu Ala Tyr Thr		
	355	360	365
20	Ser Lys Gly Ile Ala Asp Gln Glu Leu Ile Ala Gly Gly Asp Val Lys		
	370	375	380
	Tyr Thr Thr Trp Met Phe Glu Thr Gln Pro Ile Asp Ala Leu Gly Val		
25	385	390	395 400
	Pro Ser Ala Gly Thr Glu Glu Asn Thr Glu Lys Ile Pro Glu Leu Ala		
	405	410	415
30	Lys Gly Asp Val Cys Thr Ala Arg Trp Met Phe Glu Thr Arg Pro Leu		
	420	425	430
	Asp Ser Met Asn Lys Met His Glu Trp Glu Asp Glu Thr Ala Ser Thr		
	435	440	445
35	Phe Ile Lys Asp Ile Thr Gly Gly Asp Val Lys Thr Val Arg Tyr Met		

	450	455	460
	Phe Glu Thr Gln Gln Leu Asp Gln Leu Gly Gln Leu His Ser Val Asp		
	465	470	475 480
5	Glu Met Asn Leu Leu Gln Leu Arg Ser Glu Leu Lys Glu Ile Lys Gly		
	485	490	495
	Asn Val Lys Arg Ser Ile Lys Cys Phe Glu Thr Gln Pro Leu Tyr Val		
10	500	505	510
	Ile Arg Asp Gly Ser Gly Gln Met Leu Glu Ile Lys Thr Val Gln Arg		
	515	520	525
15	Glu Asp Ile Glu Lys Gly Asp Val Arg Thr Ala Arg Trp Met Phe Glu		
	530	535	540
	Thr Gln Pro Leu Asp Thr Ile Lys Gln Asp Ile Thr Glu Ile Lys Val		
	545	550	555 560
20	Val Arg Gly Ile Ser Met Glu Glu Asn Val Lys Gly Glu Val Gly Arg		
	565	570	575
	Ala Arg Trp Leu Phe Glu Thr Gln Pro Leu Glu Lys Ile Lys Glu Glu		
25	580	585	590
	Ser Gly Glu Ala Val Leu Lys Thr Glu Ala Val Val Gly Ile Asp Val		
	595	600	605
30	Ser Lys Lys Cys Trp Met Phe Glu Thr Gln Pro Leu Asp Thr Leu Lys		
	610	615	620
	Gln Ser Pro Asp Thr Glu Ser Val Ser Pro Glu Glu Arg Ile Gly Gly		
	625	630	635 640
35	Asp Val Lys Thr Thr Lys His Leu Leu Glu Thr Leu Pro Ile Glu Ala		

	645	650	655
	Leu Lys Asp Ser Pro Asp Val Gly Lys Leu Gln Lys Ile Thr Ala Ser		
	660	665	670
5	Glu Glu Glu Lys Gly Asp Val Lys His Gln Lys Trp Val Phe Glu Thr		
	675	680	685
	Gln Arg Leu Glu Asp Ile Arg Glu Asp Lys Lys Glu Tyr Thr Gln Thr		
10	690	695	700
	Val Lys Leu Glu Ala Val Asp Arg Gly His Val Lys Asn Glu Thr His		
	705	710	715
	Ile Phe Glu Ser Asn Asn Leu Ile Lys Val Asp Ala Ser His Gln Ile		
15	725	730	735
	Glu Val Glu Gly Val Thr Arg Gly Thr Val Glu Leu Asn Lys Ser Leu		
	740	745	750
20	Phe Glu Thr Thr Pro Leu Tyr Ala Ile Gln Asp His Leu Gly Lys Tyr		
	755	760	765
	His Gln Val Lys Thr Val Gln Gln Glu Glu Ile Val Arg Gly Asp Val		
25	770	775	780
	Arg Ser Cys Arg Trp Leu Phe Glu Thr Arg Pro Ile Asp Gln Phe Asp		
	785	790	795
	Glu Ser Leu His Lys Phe Gln Ile Ile Arg Gly Ile Ser Ala Gln Glu		
30	805	810	815
	Ile Gln Ala Gly Asn Val Lys Ser Ala Arg Trp Leu Phe Glu Thr Gln		
	820	825	830
35	Pro Leu Asp Ser Ile Lys Tyr Phe Ser Asn Val Glu Glu Thr Asp Ser		

	835	840	845
	Lys Thr Glu Gln Ser Thr Asp Ile Val Lys Gly Asp Val Lys Thr Cys		
	850	855	860
5	Lys Trp Leu Phe Glu Thr Gln Pro Met Glu Ser Leu Tyr Glu Lys Ala		
	865	870	875 880
	Ser Leu Met Thr Asn Ser Glu Asp Ile His Lys Gly Asp Val Arg Thr		
10	885	890	895
	Cys Met Trp Leu Phe Glu Thr Gln Pro Leu Asp Ala Ile Lys Asn Asp		
	900	905	910
15	Ser Glu Ala Thr Val Lys Leu Gln Thr Val Lys Gln Glu Glu Ile Gln		
	915	920	925
	Gly Gly Asp Val Arg Thr Ala Cys Leu Leu Phe Glu Thr Glu Asn Leu		
20	930	935	940
	Asp Asn Ile Gln Gly Gly Glu Gly Lys Glu Thr Lys Pro Val Glu Met		
	945	950	955 960
	Asp Ile Glu Ser Gly Asp Val Ser Gly Met Lys Tyr Lys Phe Glu Asn		
25	965	970	975
	Gln Ser Leu Asp Ser Ile Ser Cys Ser Ser Glu Asn Val Leu Asn Lys		
	980	985	990
30	Ile Lys Thr Leu Lys Ile Glu Asp Ile Gln Lys Gly Asn Val Leu Asn		
	995	1000	1005
	Cys Arg Trp Leu Phe Glu Asn Gln Pro Ile Asp Met Ile Lys Glu Asn		
	1010	1015	1020
35	Gln Glu Gly Asp Gly Leu Val Lys Thr Val Thr Asp Ile Gln Gly Gly		

1025	1030	1035	1040
Asp Val Arg Lys Gly Cys Phe Ile Phe Glu Thr Phe Ser Leu Asp Glu			
	1045	1050	1055
5	Ile Lys Asp Glu Ser Asp Val Ile Ser Thr Arg Gln Thr Asn Thr Glu		
	1060	1065	1070
Glu Val Ile Lys Gly Asp Val Lys Ser Tyr Lys Met Leu Phe Glu Thr			
10	1075	1080	1085
Gln Pro Leu Tyr Ala Ile Gln Asp Gln Glu Gly Phe Tyr His Glu Val			
	1090	1095	1100
15	Thr Thr Val Lys Lys Glu Glu Thr Ile His Gly Asp Val Arg Gly Thr		
	1105	1110	1115
			1120
Arg Trp Leu Phe Glu Thr Lys Pro Leu Asp Ser Ile Asn Ala Ser Glu			
	1125	1130	1135
20	Asp Val Tyr Ile Ile Lys Ser Val Thr Gln Glu Asp Ile Gln Lys Gly		
	1140	1145	1150
Asp Val Ser Ser Val Arg Tyr Arg Phe Glu Thr Gln Pro Leu Asp Met			
25	1155	1160	1165
Ile Ser Asp Lys Ser His Asn Ile Met Pro Thr Ile Asp His Ile Gln			
	1170	1175	1180
30	Gly Gly Asn Val Gln Met Asn Lys Gln Leu Phe Glu Ser Glu Gly Gly		
	1185	1190	1195
			1200
Asp Lys Lys Asn Tyr Val Arg Thr Val Ser Ile Asn Glu Ile Gln Lys			
	1205	1210	1215
35	Gly Asn Val Lys Thr Ser Thr Trp Leu Phe Glu Thr His Ser Ile Asp		

	1220	1225	1230
	Glu Leu Gly Glu Val Ser Thr Tyr Glu Asn Ile Lys Thr Val Thr Gln		
	1235	1240	1245
5	Glu Asp Val Gln Lys Gly Asp Val Lys Gln Ala Val Trp Leu Phe Glu		
	1250	1255	1260
	Asn Gln Thr Leu Asp Ser Ile Lys Glu Leu Asp Glu Ser Asp Thr Lys		
10	1265	1270	1275 1280
	Ile Thr Lys Glu Glu Ile Pro Pro Ser Asp Val Lys Thr Thr Thr Trp		
	1285	1290	1295
15	Leu Phe Glu Thr Thr Pro Ile His Glu Phe Asn Glu Thr Arg Ile Glu		
	1300	1305	1310
	Lys Glu Glu Ile Ile Gly Lys Ser Ile Lys Glu Thr Leu Glu Asp Leu		
	1315	1320	1325
20	Tyr Ser Gln Arg Val Val Glu Ala Pro Gly Ile Ile Ile Glu Ala Asp		
	1330	1335	1340
	Glu Val Gly Asp Val Arg Met Ala Lys Tyr Lys Leu Met Asn Gln Arg		
25	1345	1350	1355 1360
	Thr Pro Glu Ile Gln Lys Glu Glu Val Ile Arg Ala Asp Leu Gly Asn		
	1365	1370	1375
30	Ile Met Met Asn Leu Leu Ser Gln Arg Asp Cys Thr Lys Lys Glu Ile		
	1380	1385	1390
	Phe Ile Ser Glu Glu Glu Lys Gly Asn Val Asn Phe Thr Lys Thr Gln		
	1395	1400	1405
35	Leu Leu Asn Arg Ser Met Glu Phe His Ala Glu Lys Glu Glu Ile Val		



	1410	1415	1420	
	Arg Gly Asp Val Lys Gln Ala Ile Gln Lys Leu Phe Ser Glu Glu Arg			
	1425	1430	1435	1440
5	Cys Ala Lys Arg Gly Ile Leu Ile Gln Glu Asp Glu Lys Gly Asp Val			
	1445	1450	1455	
	Asn Met Thr Ile Tyr Cys Leu Leu His Glu Asn Ala Gly Asp Lys Thr			
10	1460	1465	1470	
	Lys Arg Glu Asp Ile Leu Gly Gly Asp Val Arg Arg Thr Ile His Asn			
	1475	1480	1485	
15	Leu Leu Ser Ser Ala Ser Asn Asp Lys Ile Ser Glu Arg Thr Lys Ile			
	1490	1495	1500	
	Asp Ala Ser Glu Arg Gly Asn Val Gln Phe Phe Thr Thr Cys Ile Glu			
20	1505	1510	1515	1520
	Thr Gly Ala Leu Asp Tyr Leu Lys Gln Leu Gln Thr Gly Ser Asn Glu			
	1525	1530	1535	
	Thr Leu Thr Ala Arg Lys Gln Glu Gly Glu Glu Glu Ile Ile Gly Gly			
25	1540	1545	1550	
	Asp Val Glu Gly Thr Lys Phe Leu Leu Lys Lys Arg Gln Ser Ser Ile			
	1555	1560	1565	
30	Glu Arg Thr Val Ser Glu Thr Asp Ile Ile Pro Gly Asp Val Arg Asn			
	1570	1575	1580	
	Thr Val Lys Val Phe Met Thr Glu Pro Gln Ser Ala Ser Phe Lys Thr			
35	1585	1590	1595	1600
	Ala Lys Glu Glu Ile Val Lys Gly Asp Leu Lys Ser Thr Leu Asn Ser			

	1605	1610	1615
	Leu Asn Gln Ala Met Asn Gln Lys Val Val Ala Lys Thr Glu Asp Ile		
	1620	1625	1630
5	Met Lys Asp Asp Lys Ala Ala Ile Leu Lys Ser Leu Lys Glu Ser Gly		
	1635	1640	1645
	Gly Arg Gln Lys Glu His Lys Gln Ser Ala Ser Ile Ser Ser Asp Ile		
10	1650	1655	1660
	Gly Gln Ala Ile Glu Cys Leu Glu Lys Ala Thr Asn Thr Arg Thr Glu		
	1665	1670	1675
			1680
15	Ile Leu Lys Lys Glu Leu Ile Leu Asp Asp Leu Lys Thr Ser Leu Arg		
	1685	1690	1695
	Ser Leu Lys Glu Glu Gln Tyr Ser Phe Lys Glu Val Gly Lys Gln Gly		
	1700	1705	1710
20	Met Val Lys Asp Val Leu Gly Phe Ser Glu Arg Gln Glu Leu Gly Ile		
	1715	1720	1725
	His Pro Ala Ala Val Gln Arg Glu Lys Lys Ser Leu Leu Gln Pro Val		
25	1730	1735	1740
	Pro Gly Pro Cys Glu Pro Ala Ile Arg Gln Gln Ala Gly Pro Gly Pro		
	1745	1750	1755
			1760
30	Leu Asp Glu Ala Thr Gln Lys Ser Cys His Arg Ser Leu Thr Glu Glu		
	1765	1770	1775
	Arg Thr Glu Ala Asn Leu Pro Lys Ala Pro Lys Gly Thr Val Lys Ile		
	1780	1785	1790
35	Val Ile Asp Arg Glu Gln Asn Asn Asp Ala Leu Glu Lys Ser Leu Arg		

	1795	1800	1805
	Lys Met Ser Asn Ser Glu His Arg Ala Met Lys Asn Val Leu Asp Met		
	1810	1815	1820
5	Gly Asp Arg Arg Gly Val Trp Thr Glu Ser Lys Glu Cys Leu Cys Ser		
	1825	1830	1835 1840
	Asp Asp His Met Ser Lys Tyr Val Ser Ala Ser Met Ser Arg Lys Lys		
10	1845	1850	1855
	Ser Leu Lys Thr Lys Glu Ser Glu Asn Val Arg Glu Ser Lys Asp Asp		
	1860	1865	1870
15	Val Ser Ser Thr Gln Ser Val Asp Lys Thr Phe Arg Lys Gln Gln Thr		
	1875	1880	1885
	Gln Asn Cys Glu Leu Gly Lys Asp His Gln Lys Ser Gln Phe Gln Asp		
	1890	1895	1900
20	Ser Tyr Ala Lys Asn Gln Lys Asn Thr Gln Asn Ile Ser Met Ser Ala		
	1905	1910	1915 1920
	Glu Thr Gln Ser Tyr Arg Pro Asp Pro Thr Gln His Pro Val Ser Asn		
25	1925	1930	1935
	Pro Ala Gly Glu Thr Leu Glu Met Thr Arg Asp Phe Gln Lys Gln Ala		
	1940	1945	1950
30	Leu Ile Arg Gln Glu Lys Gln Asn Ser Asn Lys Asp Met Arg Lys Asn		
	1955	1960	1965
	Asp Met Gly Leu Gln Pro Leu Pro Val Gly Lys Asp Ala His Ser Ala		
	1970	1975	1980
35	Pro Gly Val Thr Val Ser Gly Lys Asn His Lys Arg Thr Gln Ala Pro		

	1985	1990	1995	2000
	Asp Lys Lys Gln Arg Ile Asp Val Cys Leu Glu Ser Gln Asp Phe Leu			
		2005	2010	2015
5	Met Lys Thr Asn Thr Ser Lys Glu Leu Lys Met Ala Met Glu Arg Ser			
	2020	2025	2030	
	Phe Asn Pro Val Asn Leu Tyr Pro Asp Cys Gly Val Lys Glu Asn Glu			
10	2035	2040	2045	
	Asp Ala Leu Pro Pro Pro Ser Pro Pro Pro Pro Pro Pro Ser Asn Ala			
	2050	2055	2060	
15	Ser Ser Glu Ile Glu Phe Pro Leu Pro Pro Pro Pro Ile Met Leu			
	2065	2070	2075	2080
	Leu Pro Glu Lys Asn Glu Phe Pro Pro Ser Ser Pro Thr Glu Lys Ser			
	2085	2090	2095	
20	Arg Ala Glu Leu Glu Ser Leu Pro Thr Leu Pro Leu Pro Pro Pro Pro			
	2100	2105	2110	
	Gly Asp Glu Lys Ser Asp Gln Glu Cys Leu Pro Thr Ser Leu Pro Pro			
25	2115	2120	2125	
	Pro Pro Pro Thr Ala Pro Ser Gln Pro Ala His Leu Leu Ser Ser Ser			
	2130	2135	2140	
30	Val Leu Glu His His Ser Glu Ala Phe Leu Gln Gln Tyr Ser Arg Lys			
	2145	2150	2155	2160
	Glu Thr Leu Asp Ser His Gln Leu His Ser Gln Ala Lys Ile Leu Thr			
	2165	2170	2175	
35	Gly Lys Ser Pro Pro Pro Thr Leu Pro Lys Pro Lys Leu Pro Glu Arg			

	2180	2185	2190
	Ile Lys Ala Lys Met Ser Gln Asp Ser Pro Ser Gly Glu Leu Glu Arg		
	2195	2200	2205
5	Ser Leu Ser Asp Val Glu Ile Lys Thr Thr Leu Ser Lys Asp Gln Lys		
	2210	2215	2220
	Ser Ser Leu Val Ala Glu Ser Arg Glu His Thr Glu Ala Lys Gln Glu		
10	2225	2230	2235 2240
	Val Phe Arg Lys Ser Leu Gly Arg Lys Gln Leu Ser Ile Ser Ser Ala		
	2245	2250	2255
15	Asn Ser Leu Ser Gln Thr Val Pro Glu Ile Pro Ala Pro Lys Glu Lys		
	2260	2265	2270
	Gln Thr Ala Pro Leu Val Lys Ser His Ser Phe Pro Ser Gly Ser Glu		
	2275	2280	2285
20	Gln Gln Ser Pro Lys Pro Tyr Met Arg Lys Phe Lys Thr Pro Leu Met		
	2290	2295	2300
	Ile Ala Glu Glu Lys Tyr Arg Gln Gln Arg Glu Glu Leu Glu Lys Gln		
25	2305	2310	2315 2320
	Arg Arg Glu Ser Ser Cys His Ser Ile Ile Lys Thr Glu Thr Gln His		
	2325	2330	2335
30	Arg Ser Leu Ser Glu Lys Glu Lys Glu Thr Glu Leu Gln Lys Ala Ala		
	2340	2345	2350
	Glu Ala Met Ser Thr Pro Arg Lys Asp Ser Asp Phe Thr Arg Ala Gln		
	2355	2360	2365
35	Pro Asn Leu Glu Pro Lys Ser Lys Ala Val Ile Ala Ser Glu Cys Ser		

	2370	2375	2380	
	Glu Ser Gln Leu Ser Thr Ala Ser Ala Leu Thr Val Ala Thr Glu Arg			
	2385	2390	2395	2400
5	Leu Gln His Val Leu Ala Ala Ser Asp Asp Lys Leu Thr Leu Arg Arg			
	2405	2410	2415	
	Glu Gly Thr Gln Asn Ser Ser Asp Thr Leu Gln Ser Lys Thr Ala Cys			
10	2420	2425	2430	
	Glu Ile Asn Gln Ser His Lys Glu Cys Arg Thr Glu Gln Thr Phe Glu			
	2435	2440	2445	
15	Gln His Val Glu Lys Leu Pro Phe Pro Gln Thr Lys Pro Ile Ser Pro			
	2450	2455	2460	
	Ser Phe Lys Val Lys Thr Ile Arg Leu Pro Ala Leu Asp His Thr Leu			
	2465	2470	2475	2480
20	Thr Glu Thr Asp Leu Ser Ser Glu Arg Arg Val Lys Gln Ser Glu Ile			
	2485	2490	2495	
	Asp Val Gln Thr Ser Thr Lys Glu Met Asn Lys Glu Ile Lys Lys Thr			
25	2500	2505	2510	
	Glu Val Ser Thr Gln Cys Asp Asn Lys Gln Ser Val Ala Glu Lys Tyr			
	2515	2520	2525	
30	Phe Gln Leu Pro Lys Thr Glu Lys Arg Val Thr Val Gln Met Pro Lys			
	2530	2535	2540	
	Asp Tyr Ala Ala Lys Ser His Gln Ser Lys Leu Gln Thr Val Pro Lys			
	2545	2550	2555	2560
35	Lys His Gly Gly Leu Gly Glu Phe Asp Arg Gly Asn Val Leu Gly Arg			

	2565	2570	2575
	Glu Gly Lys Asn Gln Asp Ser Ser Met Ser Ser Thr Lys Glu Ser Arg		
	2580	2585	2590
5	Val Ile Val Glu Arg Lys Gln Glu His Leu Gln Asp Gln Ser Val Pro		
	2595	2600	2605
	Arg Leu Val Gln Gln Lys Ile Ile Gly Glu Ser Leu Asp Ser Arg Val		
10	2610	2615	2620
	Gln Asn Phe Gln Gln Thr Gln Thr Gln Thr Ser Arg Ile Glu His Lys		
	2625	2630	2635 2640
15	Glu Leu Ser Gln Pro Tyr Ser Glu Lys Lys Cys Leu Arg Asp Lys Asp		
	2645	2650	2655
	Lys Gln Gln Lys Gln Val Ser Ser Asn Thr Asp Asp Ser Lys Gln Glu		
	2660	2665	2670
20	Ile Thr Gln Lys Gln Ser Ser Phe Ser Ser Val Arg Glu Ser Gln Gln		
	2675	2680	2685
	Asp Gly Glu Lys Cys Ala Ile Asn Ile Leu Glu Phe Leu Arg Lys Arg		
25	2690	2695	2700
	Glu Glu Leu Gln Gln Ile Leu Ser Arg Val Lys Gln Phe Glu Ala Asp		
	2705	2710	2715 2720
30	Ser Asn Lys Ser Gly Leu Lys Thr Phe Gln Thr Leu Leu Asn Ile Ala		
	2725	2730	2735
	Pro Val Trp Leu Ile Ser Glu Glu Lys Arg Glu Tyr Gly Val Arg Val		
	2740	2745	2750
35	Ala Met Glu Asn Asn Leu Glu Lys Val Lys Glu Glu Ile Ile His Ile		

	2755	2760	2765
	Lys Thr Gln Ala Glu Glu Met Leu Val His Cys Glu His Val Ile Arg		
	2770	2775	2780
5	Thr Ala Met Met Ala Ser Gln Thr Gly Lys Gln Lys Asp Lys Pro Thr		
	2785	2790	2795 2800
	Asn Leu Asn Glu Met Pro Leu Lys Val Ser Asn Val Asn Leu Ser Ser		
10	2805	2810	2815
	His Lys Gly Thr Glu Gln Lys Glu Ser Lys Ile Val Glu Glu Lys Leu		
	2820	2825	2830
15	Ala Ser Arg Gln Val Ala Thr His Ser Glu Ala Ala Thr His Asn Pro		
	2835	2840	2845
	Ala Lys Thr Tyr Gln Glu Ala Lys Gly Asp Asp Ser Lys Met Ala Pro		
	2850	2855	2860
20	Pro Ser Leu Lys Thr Arg Pro Pro Ser Pro Thr Phe Ile Thr Ile Glu		
	2865	2870	2875 2880
	Ser Thr Ala Arg Arg Ala Glu Thr Ser Thr Lys Ser Glu Leu Ser Gln		
25	2885	2890	2895
	Ser Pro Lys Asn Asn Ser Cys Val Glu Pro Leu Pro Arg Arg Pro Met		
	2900	2905	2910
30	Glu His Thr Ser Arg Leu Pro Arg Thr Ser Thr Ser Pro Ser Pro Pro		
	2915	2920	2925
	Arg Ser Arg Ser Glu Gln Leu Val Arg Leu Lys Asp Thr Thr Ala Arg		
	2930	2935	2940
35	Leu Ala Lys Gly Thr Ile Pro Cys Ser Pro Gly Thr Pro Val Pro Val		



	2945	2950	2955	2960
	Val Glu Lys Arg Ser Glu Val Val Met Ser Pro Ala Thr Leu Arg Arg			
		2965	2970	2975
5	Gln Ile Lys Ile Glu Ser Arg Gly Gly Asp Ser Pro Pro Thr Ile Thr			
		2980	2985	2990
	Ile Pro Val Ser Val Asn His His Val Val Ser Gly Ser Phe Arg Glu			
10		2995	3000	3005
	Ser Val Asp Ala Gln Glu Ala Val Lys Lys Thr Glu Lys Thr Glu Thr			
		3010	3015	3020
15	Tyr Val His Lys Asp Lys Lys Asn Ser Val Ser Ser Ala Met Pro Glu			
		3025	3030	3035
				3040
	Thr Glu Ser Tyr Asp Ala Val Glu Ile Ile Arg Lys Val Glu Gly Pro			
		3045	3050	3055
20	His Leu Ser Glu His Arg Glu Arg Phe Glu Ala Thr Asn Gln Thr Val			
		3060	3065	3070
	Gln Met Ala Glu His Phe Leu Asn Gly His Glu Asn Glu Val Asn Arg			
25		3075	3080	3085
	Trp Phe Arg Glu Phe Glu Asn Gly Pro Val Phe Gly Ala Lys Thr Glu			
		3090	3095	3100
30	Arg Arg Ala Tyr Ala Asn Gly Glu Ile Asn His Asn Met Lys Gln Glu			
		3105	3110	3115
				3120
	Ser His Thr Phe Cys Lys Glu Glu Phe Gly Leu Glu Ser Ser Glu Thr			
		3125	3130	3135
35	Ala Asn Phe Thr Gly Phe Ser Tyr Arg His Pro Arg Glu His Arg Ala			

	3140	3145	3150
	Lys Ala Pro Ala Thr Gln Pro Arg Val His Ser Glu Ala Arg Ala Leu		
	3155	3160	3165
5	Asn Glu His Phe Leu Ser Val Asp Ala Phe Asp Ser Gln Ile Val Glu		
	3170	3175	3180
	Ser Gln Val Ala Thr Ser Ser Ser Arg Ser Ser Glu Ala Gly Arg Ser		
10	3185	3190	3195 3200
	Gly Phe Asp Phe Lys His Ala Pro Pro Thr Tyr Glu Asp Val Ile Ala		
	3205	3210	3215
15	Gly His Ile Leu Asp Ile Ala Asp Ser Pro Thr Asn Leu Arg Arg Asn		
	3220	3225	3230
	Phe Gln Lys Thr Trp Gln Glu Ser Glu Arg Val Phe Lys Ser Val Gly		
	3235	3240	3245
20	Tyr Glu Thr Ser Asp Ala His Ala Thr Glu Met Ser Arg Ala Phe Gln		
	3250	3255	3260
	Glu Glu Leu Ala Phe Leu Ser Glu Thr Val Gly Pro Arg Gln Gly Asn		
25	3265	3270	3275 3280
	Leu His Asn Leu Ser Lys Asp Gly Leu Ser Asn Gly Val Pro Arg Ser		
	3285	3290	3295
30	Arg Pro Ala Glu Phe Ser		
	3300		
	<210> 2		
35	<211> 12178		
	<212> DNA		

&lt;213&gt; Rattus rattus

&lt;400&gt; 2

agctggctct cactctgctg gttgctttca ggggactggg aaatttgctg tatctcaaac 60  
 5 agggagggaac cttccgagtg aagagttgca aatccataga gcattttctac ggagataggg 120  
 tcaattcttg taaaaagaga ctttcaacct tactaagccg ggagacgtga gtactgctgg 180  
 gactgaggac cagtcggatc tcctagaggc gctgtccctg aaggagagga tggctaggta 240  
 ccaggcagct gtttcacggg gcgacaccog cagcttctcg gctaattgtca tggaagaatc 300  
 agacttgtgc accgtgcctg gtggtttagc caagatgaag agacaatttg aaaaggatga 360  
 10 aatgacttca acctgcaatg ctttctctga gtatcaatac caacatgaga gcagatctga 420  
 gcaggaggca atccacaaca ggcaagaaat aagaaggaat gaagaagaag tttctaaagg 480  
 acacagaact gatgtcttca aagctgaaat gatgtcacat cttgaaaagc acacggagga 540  
 aacaaaccaa gcttcacagt ttctgcaata tgttcaagaa acagtcattg atacaccaga 600  
 agacgaagag attcctaagg ttccactaa gattttaaaa gagcaatttg aaaagactgc 660  
 15 ccaggaaaac ttctctact ctgataaaga aacaacaacc ccagccaagt gtataaagat 720  
 tgaaaatgac agtgaagaaa ctttaaagcc atcatcggct atgggtacct cttcttatac 780  
 ttccagccagg caaagcaagg aaacttcaac ctcaagttat agtaatcaca gtctgacttc 840  
 aacaatcctg gcacaagaaa agggcactcc ttccaggaaag atggaagaat ttctctctcc 900  
 cccacctgat gtttttcaaa caccaatgga tgtgacagca ttttccagct cccctgaatt 960  
 20 cccagccct cctagaagac tgccaatgcc cagagatgta tattccaagc aacgaaattt 1020  
 gtatgaatta aaccgtttat ataggcatat ccatcctgag ttaagaaaaa acttagaaaa 1080  
 agattatatac agtgagggtt ctgaaattgt ttctagtcac ataaactcag ggaactcgat 1140  
 atcagcaggt gtacaacaag ctcggtatgt ttctgaaaat acgaatgaca gttctcagaa 1200  
 agatttgagc tcagaaagag aaaacctgga gtgggatgaa attctgaaag gagagggtgca 1260  
 25 gtcaattcga tggatttttg agaactcagcc attagattct atcaaccaag gttttacaga 1320  
 tgaagcgtac acttccaaag gcattgctga ccaagaactc attgctgggg gtgacgtgaa 1380  
 atatacgact tggatgtttg aaactcagcc aatagatgca ttgggagtgc cttctgctgg 1440  
 cactgaagaa aacactgaga aaattcctga gctagctaaa ggagatgttt gcacagcaag 1500  
 gtggatgttt gaaacaaggc ctttagactc aatgaacaaa atgcatgaat gggaagatga 1560  
 30 aacggcatct acttttataa aggacataac tgggggagat gtcaagactg tgagatacat 1620  
 gtttgaaact caacaactgg atcaacttgg acagcttcac tcagtggatg aaatgaactt 1680  
 attacaactc agatcagagc tcaagaaat taaaggaaat gttaagagaa gcataaaatg 1740  
 ttctgaaact caaccactgt atgtcattag agatggttca ggccaaatgc tagaaattaa 1800  
 aactgtgcag agagaagaca ttgaaaaggg agatgtaagg acagcacgct ggatgtttga 1860  
 35 aacgcagcct ttggacacaa taaaacaaga catcacggaa attaaagtgt ttcgaggaat 1920  
 atccatggag gaaaatgtca aaggcgaggt gggtagagca aggtggttat ttgaaactca 1980

accactggag aaaatcaaag aagagtcagg tgaggctgtc ctgaaaacag aagcagttgt 2040  
 agggatagat gtgtctaaaa agtgttggat gtttgaaacg cagccattag acactctaaa 2100  
 acaatctcct gatacagaga gtgtatcacc tgaagagagg ataggagggtg acgtaaaaac 2160  
 caccaaaacat ctgttagaaa cactcccaat agaggcctta aaagacagcc cagatgttgg 2220  
 5 aaagcttcaa aaaatcactg cctctgagga agaaaagggc gatgttaagc accaaaaatg 2280  
 ggtttttgaa actcaacggt tagaagatat tagagaagat aagaaggaat ataccagac 2340  
 agtgaagcta gaagcagtg acagagggca tgtgaagaac tatacacata tcttcgaatc 2400  
 caataatcta attaagggtg atgcatcaca tcaatttgag gtggaaggag tcacaagagg 2460  
 cactgtggag ttgaataaat ctctctttga gacaaccca ctgtatgcca ttcaagacca 2520  
 10 tcttgaaaa taccaccaag taaagacagt ccagcaagaa gaaatagtaa ggggtgatgt 2580  
 aagaagctgt agatggcttt ttgaaacaag gccattgac caatttgacg aaagccttca 2640  
 taaatttcag ataattagag gaatatctgc tcaagaaata caggcaggga atgtgaaatc 2700  
 agctagggtg ctgtttgaga cccaacctct tgattcaatt aaatatttta gcaacgtgga 2760  
 agaaacagac agcaaaactg aacagagtac tgatatgtt aagggggatg tcaaaacctg 2820  
 15 taaatggcta ttgaaaccc agccaatgga gtctctttat gaaaaagctt ccttgatgac 2880  
 gaactcagaa gatattcaca aagggtgatgt tagaacttgt atgtggctat ttgaaactca 2940  
 gccacttgat gccataaaaa atgactctga agccacagta aaactgcaaa ctgtgaaaca 3000  
 ggaggagata caaggtgggg atgtccggac agcatgtctt ctttttgaga cagaaaatct 3060  
 ggacaacata caggcggtg aagggaaga aacgaagccc gtggagatgg atatagaatc 3120  
 20 tggggatgtc tctggcatga agtataagtt tgaaaatcag tccttagact ctataagttg 3180  
 cagttcggag aatgttttga ataagatcaa aacctaaaa atcgaagaca ttcagaaagg 3240  
 caatgtttta aattgtaggt ggctatttga aaatcaacct atcgatatga taaaagaaaa 3300  
 tcaagaaggt gatggattgg ttaagacagt gacagacata cagggtggag atgtgagaaa 3360  
 gggatgcttc atttttgaga cgttttcttt agatgagatt aaagatgcct ctgatgtcat 3420  
 25 cagcaccaga caaacaata ccgaggaggt aataaaaggt gatgtaaaaa gctacaagat 3480  
 gctttttgaa acacaaccac tctatgcgat tcaagacca gaagggtttt atcatgaagt 3540  
 gacaacagtt aaaaaagaag aaactattca tggagatgta cgaggaacaa ggtggctctt 3600  
 tgaaacaaaa ccgttagact caattaacgc atcagaagat gtatacatta ttaaatctgt 3660  
 cactcaggaa gacattcaga agggggatgt gagtctgtc agataccgat ttgaaacaca 3720  
 30 accactggat atgatttcag acaaatcaca taatattatg cccactattg accatattca 3780  
 aggaggcaat gtgcagatga ataaacaact attcgagtct gaagggtgtg acaagaagaa 3840  
 ttatgtaaga acagttagca tcaatgaaat acaaaagggc aatgttaaga cttctacttg 3900  
 gctctttgaa actcacagca tagatgagct gggagaagtg tccacctatg aaaatatcaa 3960  
 gacagtcacc caggaagacg tgcagaaagg tgacgtgaag aaaatatcaa ggctttttga 4020  
 35 aaatcagaca ttggattcca ttaaggaact tgatgaaagt gacacaaaa taaccaaaga 4080  
 agaaattcct ccgtcagatg tcaagacaac aacgtggctc ttgaaacga cacctattca 4140

cgaatttaat gaaactagaa tagaaaagga agaaattatt ggtaaaagca ttaaagaaac 4200  
 cttagaagac ctctactctc aaagagtggg tgaagctccc ggaatcatca ttgaagctga 4260  
 tgaagttggg gatgtcagaa tggccaaata caagctcatg aaccaaagga ctctgagat 4320  
 ccagaaggaa gaagttatca gagctgacct tggaaacata atgatgaact tgctttccca 4380  
 5 aagagactgc acaaaaaagg agatatttat cagtgaagag gagaaggga atgtcaattt 4440  
 tactaaaacc cagttattaa acagatcaat ggaattccat gctgaaaagg aagagatagt 4500  
 aagaggggat gtaaaacaag caatccaaaa gctgttctct gaggaagggt gtgcaaagag 4560  
 aggcatatta attcaagaag atgaaaagg agatgttaac atgactatct attgtcttct 4620  
 tcatgagaat gctggcgaca agactaagcg tgaagacata ctgggagggt atgtgagaat 4680  
 10 cactattcat aacctgttgt cttccgcatc aaatgataaa atatctgaaa ggacaaaaat 4740  
 cgatgcatcg gagaggggaa atgttcagtt cttcacaaca tgcatagaaa ctggagcttt 4800  
 ggattacctc aagcaactcc aaacagggtc aaatgaaaca ctcacagcta gaaagcaaga 4860  
 aggggaggaa gaaataattg gtggtgatgt tgagggaaca aaattcttac taaagaaaag 4920  
 acagtcttct attgaacgca ctgttagtga aactgatato atcccaggag atgtgcgtaa 4980  
 15 tacagttaaa gtcttcatga cggagcccca gagtgcactt ttttaagacag cgaaagaaga 5040  
 gattgtaaaa ggtgatttga aatcaaccct gaattctctc aaccaggcca tgaatcagaa 5100  
 agtagtggct aaaacagaag atattatgaa agatgacaag gcagctatac tcaagtcact 5160  
 taaggagtca ggtggcagac agaaagaaca taaacaatct gctagcatct ctagtgatat 5220  
 tgggcaagct attgagtgcc ttgaaaaggc cacaataca aggacagaaa tattgaaaaa 5280  
 20 ggagctgata ttagatgato ttaaaacatc attaaggctt ttgaaagaag aacaatacag 5340  
 tttcaaagag gttggtaaac agggaatggt caaagatgta ctaggattct cagagagaca 5400  
 agaactaggg attcatccag cagctgtcca gagagagaaa aaaagccttc ttcaaccagt 5460  
 gccaggacca tgttagccag caatcaggca gcaagcagga ccaggccctc ttgatgaagc 5520  
 tacacagaaa tcctgccatc ggtctttaac agaagaaaga actgaggcta atcttcccaa 5580  
 25 agcccctaag ggcactgtaa agattgtcat tgatcgagaa caaaacaacg atgtcttga 5640  
 gaaaagcctt aggaaaatgt ctaattcaga acatagagct atgaaaaatg ttttagacat 5700  
 gggtagacaga aggggtgtct ggacagagag caaagagtgt ctgtgtagt acgaccatat 5760  
 gagcaaatac gtaagtgcaa gcatgtcaag gaagaaaagt ctaaagacca aggaatcaga 5820  
 gaatgtgaga gaatcgaagg acgatgtgag ctccaccag tctgttgata aaacatttag 5880  
 30 gaagcaacag actcaaaact gtgaactggg gaaggatcac cagaagtctc agttccagga 5940  
 ttctatgagc aagaatcaga aaaataccca aaacattagt atgtcagcag aaacccaaag 6000  
 ttacagacca gaccctaccc aacatccagt cagcaatcca gctggagaaa cgcttgagat 6060  
 gacaagggac tticagaagc aagccttgat aagacaggaa aagcagaatt ctaataaaga 6120  
 tatgaggaaa aatgacatgg gccttcaacc tctgcctgta gggaaggacg cacacagtgc 6180  
 35 accaggagtg acagtctctg ggaaaaacca caaagaact caggcacctg acaagaaaca 6240  
 gagaattgat gtttgtctag aaagccagga ctttctaatt aagacaaata cttccaagga 6300

gttaaaaatg gcaatggaga ggtccttttaa tccagtcaac ctttaccctg actgtggtgt 6360  
 aaaagaaaat gaggacgccc ttctcctcc atctccccct cctcctcctc cttccaatgc 6420  
 gtcatctgaa attgaatttc ctctccctcc tccaccacct ataatgctgt tgcctgaaaa 6480  
 aaatgagttt cctccctcat caccacaga gaagtcaagg gctgaacttg agagcctccc 6540  
 5 aaccctgcct cttcctccac caccaggaga tgagaaatct gatcaggaat gtctaccaac 6600  
 atccctacct cctccccctc ccacagctcc atcccaacca gcacatcttc tttcctcctc 6660  
 tgtttttagaa catcacagtg aagcattttt acaacagtat tcccgaagaa aaaccttgga 6720  
 ctctcatcag cttcactcac aggctaaaat cctaacagga aaatcaccac ccccaacact 6780  
 ccccaaacc aaacttcccg agagaatcaa agctaagatg agccaggatt caccaagcgg 6840  
 10 tgaattggaa agatctctgt cagatgtgga aattaaaact accctctcaa aggatcagaa 6900  
 aagttcgtg gtggcagaaa gccgtgagca cacagaggcc aagcaagaag tattccgaaa 6960  
 aagccttgga agaaaacagc tgtcaattag ctctgcaaac tccctctctc agacagttcc 7020  
 agaaatccca gcacccaagg aaaaacagac agcaccctt gttaaattctc actcattccc 7080  
 atcaggttca gaacaacaaa gtcctaagcc ttacatgaga aaatttaaga cacccttaat 7140  
 15 gattgcggaa gaaaaataca gacagcaaag ggaagagctt gagaaacaga gacgggagag 7200  
 ttcttgccat agcatcatca aaacagaaac ccagaccgc agcttatcag agaaagagaa 7260  
 agaaacagag ttacaaaaag cagctgaggc aatgtccact ccagaaagg attcagactt 7320  
 cactagggca cagcccaacc tggaacctaa aagcaaggct gtgatcgcca gtgaatgctc 7380  
 tgaaagccag ctctctacag cttccgcatt gacagtcgt accgagaggc tccagcatgt 7440  
 20 tctagccgct tcagacgata agcttaccct gcgacgggaa ggcacacaga actcaagtga 7500  
 caccctacaa tcgaaaacag cttgtgagat taaccagagt cacaaggaat gtaggacaga 7560  
 gcaaacattt gagcaacacg tggagaagtt gcccttcccc caaaccaaac ccatttcccc 7620  
 gagtttcaaa gtgaaaacta tcaggcttcc agctctagat catacgtga ctgaaacaga 7680  
 tctcagttct gaacgccgcg taaagcaatc cgaaattgac gttcaaacca gtactaaaga 7740  
 25 aatgaataag gaaattaaga aaaccgaagt gagcacacag tgtgataata agcaatctgt 7800  
 ggctgaaaaa tattttcaat tacctaaaac agagaaacgg gtgacggtag aaatgcccc 7860  
 agactatgca gcgaaaagtc atcaaagcaa actccaaaca gttcccaaga agcatggagg 7920  
 attgggggag tttagacagag ggaatgtcct ggggagggaa ggaaaaaatc aggactcctc 7980  
 catgagcagt acaaaaagaa gcagggtaat agttgaaaga aagcaagaac atctacagga 8040  
 30 ccagagcgta ccaaggtag tccaacaaaa gattatcggg gaaagcctgg actcacgggt 8100  
 tcagaatttt cagcagacac aaacacaaac ttctaggatt gagcataaag aactgtccca 8160  
 accttacagt gagaaaaaat gtcttagaga caaggacaaa caacaaaaac aggtctcctc 8220  
 taacactgac gattcaaagc aagagataac acaaaaacaa tcttcatttt cctctgtgag 8280  
 agaatccag caggatggag aaaaatgtgc cataaatata ttggaattct tgagaaaacg 8340  
 35 tgaagaacta cagcagattt tgtctagggt aaaacagttt gaagcagatt caaataaaag 8400  
 tggccttaaa acatttcaga cactgttaaa tattgtccg gtgtggctga taagtgagga 8460

gaaaagagaa tatggagtto gtgttgccat ggagaataat ttagaaaaag tcaaagaaga 8520  
 aataatacat attaaaaactc aagcggagga gatgatcggt cactgtgaac acgtaattcg 8580  
 aacagccatg atggcttccc aaacaggaaa gcagaaagat aaacctacca atcttaatga 8640  
 aatgccactg aaagtgtcta atgttaatct cagctctcat aaaggcactg aacagaaaga 8700  
 5 aagtaaaatt gtagaagaaa aattagcatc ccgccaagta gcaacccatt ctgaggcagc 8760  
 aactcataat cctgctaaaa catatcagga ggctaagggg gacgatagta agatggctcc 8820  
 tccctctttg aaaactcgcc caccatcacc aactttcatc accatcgaat ccaactgcccg 8880  
 ccgagcagaa acatccacta agagttagct ttctcagtcc cctaaaaata acagttgtgt 8940  
 tgaacctcta ccagaaagac ccatggagca tacatctagg cttcccagaa caagtacatc 9000  
 10 accttcccca ccaaggagtc gttcagaaca acttgtcaga ctcaaagaca ccacggccag 9060  
 gttagccaaa ggcactatcc cttgttcacc aggaaccccg gttccagttg tcgagaagag 9120  
 atctgaagtt gtcattgtct cagccacact ccgaggcaa atcaagatag aaagccgtgg 9180  
 cggggactcc ccaccacca tcacaatacc tgtgagtgtg aaccaccatg tcgtcagtgg 9240  
 ttcttcaga gaatcagtag acgctcaaga ggcagtgaag aaaacagaaa aaacagagac 9300  
 15 gtacgttcat aaagacaaaa agaattctgt cagtagcgca atgccagaga ctgaaagcta 9360  
 tgacgcagtt gaaatcatcc gcaagggtga agggcccccac ctatcagaac acagggagag 9420  
 atttgaagcc accaatcaaa ctgttcaaat ggctgaacat tttctgaatg gccacgaaaa 9480  
 tgaagtaaac agatggttta gggaatttga gaatggcca gttttcggag caaagacaga 9540  
 gagaagagct tatgcaaatg gcgaaataaa ccacaacatg aaacaagaga gtcatacgtt 9600  
 20 ttgcaaggag gaatttggat tagaatcttc tgaaactgct aattttacag gcttttctta 9660  
 cagacatcct agagagcatc gagcaaaagc ccctgcaacg cagcccaggg ttactctga 9720  
 agccagagct ctcaatgagc atttttttag cgtggatgag ttcgacagtc agattgtaga 9780  
 gtcacaggta gcaacctcat catcacggag ctacagggca ggcagatctg gatttgattt 9840  
 taagcatgcc ccaccgacct atgaagatgt catcgctggc cacatcctag atattgcaga 9900  
 25 ttgcctaca aacctcagac ggaattttca aaagacatgg caggagagtg aaagagtttt 9960  
 taagagcgtg ggatatgaaa cctcggatgc acatgcgaca gaaatgagca gggccttcca 10020  
 ggaggaattg gcctttttga gtgaaactgt tgggtccaaga caaggaaatc tgcataattt 10080  
 gtcaaaagac ggtttatcca atggagtgc tcgtagcaga ccagcagaat tttcataaat 10140  
 cttgcttcag atgccaccat tgcagcagta aactgagttt gggaaattac gcatcacttc 10200  
 30 acggacaaat atactgcaag cctcacttta aacaactttt caagtctaaa ggaaattatg 10260  
 atgaaggttt tggacacaag caacataaag accggtggaa ttgcaaaaac caaagcagct 10320  
 tagttgattc tattcccagc ggagagcccg atgctcggga aaacctaca gcagatatcc 10380  
 tcttgcttgg ggatcttgcg gtacatgcag acgcttgtaa cagcaagcgg caagacaatg 10440  
 gtttgagaaa atggggggag aggggggaaat taaaaattgt ttggcctccc tgtcaggaga 10500  
 35 tgcctaagaa aaactctccc cctgaggaag aactcaaagt gaataaagct aaatggccac 10560  
 ctgagttgac catccctggt ccctcagaat ttaaaaggga gtcactgacc gaacacgtga 10620

aaatgttggg gagtcagggg caagaacaag atcacctccc tgaattgcaa ccctgccaac 10680  
 gcattttgtca gaaagaggac attacaggca tcaaagaaat aaaaggggtac gaagaaagaa 10740  
 atgatgagaa agaagcaaag ggaaaggcgc aggatacgct gaaagatgca gagggttga 10800  
 ggagtaagag aaaaagtggg atggagctta acgaccataa tgcgcatgct cagagtgatg 10860  
 5 gaaaggaaaa gaatgctcgt gctaataaac ctgacagtgc agacatttta caagttacaa 10920  
 acaccgatga tgacgatgag gtggggccag aaaatcatag ggagaacttc aataacaata 10980  
 acaataacaa ttctgtagct gtctcatcct tgaataatgg caggcagcag acatctatct 11040  
 cagaatatcc tcatgtacta cagacagcca gtgaagcaaa ctattacaca aatgaatacc 11100  
 aaattaaaaa gtttaacaat gcctctagaa tctcagagtt actgggtata tttgagtctc 11160  
 10 aaaagtctgc ctccaagaat gtcctagcct tggctctgga gagcacggct gacagaggga 11220  
 ctgcaggcag tcccatgcag ctggcactgg agcccggctt ccagcagggc ttatcagtta 11280  
 aaggggaaaag ccttgtagtc tctaacgaag taaaccctt acacattaaa ggaaaccatg 11340  
 aaaataacaa gaatgtacac cttttcttct ctaacactgt gaaaatcact tctttttcca 11400  
 agaaacataa catccttggg tgtgatttaa tagattctgt tgatcaactt aaaaatatgt 11460  
 15 catgcttgta tttaagagaa ctcgggaaaa atgtcaaag ctggcatggt gaaactgcag 11520  
 gagcggctcg gcatggtgga aaaatgtgtt ttgatgctca gagccaagag agtgcggcta 11580  
 agcctgtgtt tccagcatg cagtgccagg ctcaacatct gactgtggaa gagcagatta 11640  
 aacgggacag gtgctacagc gacagtgagg ctgactgaaa agtctttggc cacttgcagt 11700  
 tcatgctcgg gcaactgagg agcctgttct cggagaagac ctcgggatca tcgctaacct 11760  
 20 tttgatgagt ttgtaaagat cacgtttcat aatctcacca ttcacagcac attatttctt 11820  
 gtatgcgact ccataatcct tttccaccat tcaattgaga ctagtttgga tcttaatgaa 11880  
 atgctgagat gaaacatggt gaccgtgttt tcttctcaaa tggcgcattg gctacggttt 11940  
 tctgtatctt aaagtgggag agagtctgca ccgctgggtg tcatcgccac tcttatacct 12000  
 tctctatatt ttctgatgaa ataaaaatct gtcaactgag atgcaaaaaa aaaaaaaaaa 12060  
 25 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 12120  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 12178



[Document Name] Abstract

[Abstract]

[Problems to be Solved]

5 It is known that NO-mediated changes in cardiovascular remodeling occur due to a  
local increase of angiotensin convertase activity in cardiac tissues, and can be suppressed  
almost completely by ACE inhibitors and angiotensin II receptor antagonists. Many facts  
still remain unclear such as the mechanism of local activation of the renin-angiotensin system,  
and signaling. Thus, identification of genes that play important roles in the development of  
cardiovascular lesions is desired. Such genes and proteins encoded by these genes are also  
10 considered to be important in terms of the prevention and treatment of cardiac diseases.

[Means to Solve the Problems]

The present invention provides the novel actin-related cytoskeletal protein LACS and  
genes encoding the protein.

[Selected Drawings] None